Connecting via Winsock to Dialog

Logging in to Dialog

Trying 31060000009998...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ****
ENTER PASSWORD:
 ****
Welcome to DIALOG

Dialog level 05.27.00D

Last logoff: 09nov09 17:02:39
Logon file405 18nov09 16:53:59
           *** ANNOUNCEMENTS ***
                    ***
**** October 29, 2009 - Invoices to UK customers may be delayed by
postal strike. Contact dialog.billing@dialog.com to request
email delivery, or enter HELP INVOICE for details.****

*** FREE FILE OF THE MONTH: NOVEMBER
Foodline(R): SCIENCE (File 53)

Each month Dialog offers an opportunity to try out new or
unfamiliar sources by offering $100 of free searching
(either DialUnits or connect time) in specified files.
Output and Alerts charges are not included. For more
details visit: http://www.dialog.com/freefile/
and then take a moment to get familiar with
another great Dialog resource.

NEW FILES
***File 106, Harvard Business Review Fulltext, Images
***File 558, Mergent China Private Company Database
***File 457, The Lancet(R)

FILES REMOVED
***File 59, Foodline: Legal
***File 614/814, Agence France-Presse English Wire
***File 615/815, Agence France-Presse Internat'l French Wire

 >>>For the latest news about Dialog products, services, content<<<
 >>>and events, please visit What's New from Dialog at   <<<
 >>>http://www.dialog.com/whatsnew/. You can find news about   <<<
 >>>a specific database by entering HELP NEWS <file number>.   <<<
* * *

```
SYSTEM:HOME
Cost is in DialUnits
Menu System II: D2 version 1.8.0 term=ASCII
                     *** DIALOG HOMEBASE(SM) Main Menu ***

 Information:
  1.  Announcements (new files, reloads, etc.)
  2.  Database, Rates, & Command Descriptions
  3.  Help in Choosing Databases for Your Topic
  4.  Customer Services (telephone assistance, training, seminars,
etc.)
  5.  Product Descriptions

 Connections:
  6.  DIALOG(R) Document Delivery
  7.  Data Star(R)

    (c) 2003 Dialog, a Thomson business.      All rights reserved.

      /H = Help            /L = Logoff          /NOMENU = Command Mode


Enter an option number to view information or to connect to an online
 service.  Enter a BEGIN command plus a file number to search a
database
(e.g., B1 for ERIC).
? b 410

       18nov09 16:53:59 User226352 Session D1191.1
            $0.00    0.267 DialUnits FileHomeBase
     $0.00  Estimated cost FileHomeBase
     $0.00  Estimated cost this search
     $0.00  Estimated total session cost   0.267 DialUnits

File 410:The Chronolog 1991-2009/ Sep
       (c) 2009 Dialog. All rights reserved.

      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? b biochem
       18nov09 16:54:02 User226352 Session D1191.2
            $0.00    0.117 DialUnits File410
     $0.00  Estimated cost File410
     $0.00  Estimated cost this search
     $0.00  Estimated total session cost   0.384 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R) 1926-2009/Nov W3
         (c) 2009 The Thomson Corporation
```

```
  File   6:NTIS 1964-2009/Nov W4
         (c) 2009 NTIS, Intl Cpyrght All Rights Res
  File  24:CSA Life Sciences Abstracts 1966-2009/Dec
         (c) 2009 CSA.
  File  34:SciSearch(R) Cited Ref Sci 1990-2009/Nov W2
         (c) 2009 The Thomson Corp
  File  40:Enviroline(R) 1975-2008/May
         (c) 2008 Congressional Information Service
*File  40: This file is closed and will no longer update. For
similar data, please search File 76-Environmental Sciences.
  File  41:Pollution Abstracts 1966-2009/Dec
         (c) 2009 CSA.
  File  45:EMCare 2009/Nov W2
         (c) 2009 Elsevier B.V.
  File  50:CAB Abstracts 1972-2009/Nov W3
         (c) 2009 CAB International
  File  65:Inside Conferences 1993-2009/Nov 18
         (c) 2009 BLDSC all rts. reserv.
  File  71:ELSEVIER BIOBASE 1994-2009/Nov W2
         (c) 2009 Elsevier B.V.
*File  71: The file has been reloaded. Accession numbers
have changed.
  File  72:EMBASE 1993-2009/Nov 18
         (c) 2009 Elsevier B.V.
  File  73:EMBASE 1974-2009/Nov 18
         (c) 2009 Elsevier B.V.
  File  76:Environmental Sciences 1966-2009/Dec
         (c) 2009 CSA.
  File  98:General Sci Abs 1984-2009/Nov
         (c) 2009 The HW Wilson Co.
  File 103:Energy SciTec 1974-2009/Oct B2
         (c) 2009 Contains copyrighted material
*File 103: For access restrictions see Help Restrict.
  File 136:BioEngineering Abstracts 1966-2007/Jan
         (c) 2007 CSA.
*File 136: This file is closed.
  File 143:Biol. & Agric. Index 1983-2009/Oct
         (c) 2009 The HW Wilson Co
  File 144:Pascal 1973-2009/Nov W3
         (c) 2009 INIST/CNRS
  File 154:MEDLINE(R) 1990-2009/Nov 17
         (c) format only 2009 Dialog
  File 155:MEDLINE(R) 1950-2009/Nov 17
         (c) format only 2009 Dialog
  File 156:ToxFile 1965-2009/Nov W3
         (c) format only 2009 Dialog
  File 162:Global Health 1983-2009/Nov W3
         (c) 2009 CAB International
  File 172:EMBASE Alert 2009/Nov 13
         (c) 2009 Elsevier B.V.
*File 172: Due to technical issues on the supplier's side, there is
no daily update 16 & 17 November.
```

```
  File 305:Analytical Abstracts 1980-2009/Sep W4
         (c) 2009 Royal Soc Chemistry
*File 305: Alert feature enhanced for multiple files, duplicate
removal, customized scheduling.  See HELP ALERT.
  File 369:New Scientist 1994-2009/Nov W2
         (c) 2009 Reed Business Information Ltd.
  File 370:Science 1996-1999/Jul W3
         (c) 1999 AAAS
*File 370: This file is closed (no updates). Use File 47 for more
current
information.
  File 393:Beilstein Database - Abstracts 2008/Q2
         (c) 2008 Beilstein GmbH
  File 399:CA SEARCH(R) 1967-2009/UD=15121
         (c) 2009 American Chemical Society
*File 399: Use is subject to the terms of your user/customer
agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.
  File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 2006 The Thomson Corp

      Set  Items  Description
      ---  -----  -----------
? s serum (3n) sample (3n) ?teatment
>>>File 5 processing for ?TEATMENT stopped at ABSTRACT AESTHETIC
   RESTORATIVE MATERIALS DIAGN
>>>File 6 processing for ?TEATMENT stopped at ARNEGARD
>>>File 24 processing for ?TEATMENT stopped at AMINO ACID SEQUENCE
   PREDCITION
>>>File 34 processing for ?TEATMENT stopped at ACOPO
>>>File 40 processing for ?TEATMENT stopped at HOUSEPAINT
>>>File 41 processing for ?TEATMENT stopped at DARTERS
>>>File 45 processing for ?TEATMENT stopped at ATRIO-VENTRICULAR
ARRHYTHMIA
>>>File 50 processing for ?TEATMENT stopped at ALAAM
>>>File 65 processing for ?TEATMENT stopped at BERNADUS
>>>File 71 processing for ?TEATMENT stopped at ALCOHOL IN THE BLOOD
>>>File 72 processing for ?TEATMENT stopped at AGWAY
>>>File 73 processing for ?TEATMENT stopped at AEROPALYNOLOGIQUE
>>>File 76 processing for ?TEATMENT stopped at ANMV
>>>File 98 processing for ?TEATMENT stopped at CATSPER
>>>File 103 processing for ?TEATMENT stopped at ALLOW
>>>File 136 processing for ?TEATMENT stopped at DENTAL RESTORATIVE
   FORMULATIONS
>>>File 143 processing for ?TEATMENT stopped at DIPOLYDORA HUELMA
>>>File 144 processing for ?TEATMENT stopped at ACIERA CR:15-20
NI:10-15 TI
   C:0,1-0,23 H
>>>File 154 processing for ?TEATMENT stopped at ALLOCATABILITY
>>>File 155 processing for ?TEATMENT stopped at AG4L4
>>>File 156 processing for ?TEATMENT stopped at ANNEXIN A6 --ANALYSIS
--AN
```

```
>>>File 162 processing for ?TEATMENT stopped at AXIS
<------User Break------>
u!
? s serum (3n) sample (3n) (treatment or preteatment)
Processing
Processed  10 of  29 files ...
Processing
Processed  20 of  29 files ...
Completed processing all files
         4828858  SERUM
         3349774  SAMPLE
        18998347  TREATMENT
             276  PRETEATMENT
      S1     475  SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETEATMENT)
? rd s1

>>>Duplicate detection is not supported for File 393.

>>>Records from unsupported files will be retained in the RD set.
      S2     146  RD S1  (unique items)
? s s2 not PY>2006
Processing
Processed  20 of  29 files ...
Completed processing all files
             146  S2
        22778661  PY>2006
      S3     117  S2 NOT PY>2006
? rd s3

>>>Duplicate detection is not supported for File 393.

>>>Records from unsupported files will be retained in the RD set.
      S4     117  RD S3  (unique items)
?  s4 and acid
Processing
Processed  10 of  29 files ...
Processing
Processing
Processed  20 of  29 files ...
Processing
Completed processing all files
        24066014  4
        14799721  ACID
      S5 3720408  4 AND ACID
? s s4 and acid
             117  S4
        14799721  ACID
      S6      24  S4 AND ACID
? t s6/7/1-10
>>>Format 7 is not valid in file 143

 6/7/1     (Item 1 from file: 5)
```

16054360 BIOSIS NO.: 200100226199
Evaluation of detection methods for the reversed-phase HPLC determination of 3',4',5'-trimethoxyflavone in different phytopharmaceutical products and in human serum
AUTHOR: Huck Christian W (Reprint); Bonn Guenther K
AUTHOR ADDRESS: Institute of Analytical Chemistry, and Radiochemistry, Leopold-Franzens University, Innrain 52a, 6020, Innsbruck, Austria** Austria
JOURNAL: Phytochemical Analysis 12 (2): p104-109 March-April, 2001 2001
MEDIUM: print
ISSN: 0958-0344
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Quantitative determination of the major compound, 3',4',5'-trimethoxyflavone (1), in plant extracts, in tablets of Flos and of Radix Primulae veris and in human serum has been accomplished using reversed-phase HPLC with UV, fluorescence and mass spectrometric (MS) detection. Compared to UV detection, fluorescence detection showed greater selectivity, was 10-fold more sensitive and allowed the determination of 1 in human serum after sample pre-treatment by solid-phase extraction. MS detection of 1 using electrospray ionisation (ESI) interface could be improved by substituting trifluoroacetic acid with the more polar and less conductive additive acetic acid, giving rise to a 230-fold improvement in analyte detectability at the cost of an increase of only 45% in the peak width of the eluting peak at its half height. Further optimisation of the acetic acid concentration showed the highest signal intensity at 1.25% for HPLC-atmospheric pressure chemical ionisation (APCI)-MS and at 0.75% for HPLC-ESI-MS. The optimised MS method proved to be extremely selective, 50 times more sensitive than UV detection and 5 times more sensitive than fluorescence detection. Furthermore, fragment-ion spectra produced by collision induced dissociation-MS have been used as "fingerprints" for identifying compounds in the highly complex mixtures

examine.

6/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

09760076 BIOSIS NO.: 198988075191
ASSESSMENT OF AN RIBOSOMAL DNA PROBE FILTER HYBRIDIZATION ASSAY FOR THE
DETECTION OF RIFT VALLEY FEVER VIRUS RNA IN HUMAN SERUM SAMPLES FROM THE
MAURITANIAN EPIDEMIC
AUTHOR: KNAUERT F K (Reprint); MEEGAN J M; JOUAN A; KSIAZEK T G; LE GUENNO
B; SARTHOU J L; PETERS C J; DIGOUTTE J P
AUTHOR ADDRESS: DISEASE ASSESSMENT DIV, UNITED STATES ARMY MED RES INST
INFECTIOUS DISEASES, FT DETRICK, FREDERICK, MD 21701-5011, USA**USA
JOURNAL: Research in Virology 140 (1): p47-58 1989
ISSN: 0923-2516
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: The Rift Valley fever virus (RVFV) epidemic that occurred in southern Mauritania during the 1987 rainy season provided a unique opportunity to test and evaluate a recently developed, M-segment-specific, nucleic acid filter hybridization assay on a large collection of infected human serum samples. It afforded the opportunity to compare the procedure with two other methods for detecting virus: virus isolation and antigen detection by ELISA. The filter hybridization procedure employed a polyethylene-glycol-precipitation and proteinase-K-digestion sample treatment step developed specifically for preparing serum samples for hybridization. The procedure was less sensitive for detecting RVFV in the Mauritanian human viremic samples than in sera from experimentally infected monkeys used to evaluate this procedure. It was also less sensitive than an antigen detection procedure used to test the Mauritanian samples. However, we were able to detect virus RNA in a significant proportion of the virus-isolation-positive samples. Advances in sample preparation, labelling and detection procedures, and hybridization methods will improve the sensitivity, precision and ease of use of this assay and increase its value as a diagnostic tool.

6/7/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

09270216 BIOSIS NO.: 198886110137
DETERMINATION OF COPPER AND ZINC IN SERUM AND WHOLE BLOOD BY ION CHROMATOGRAPHY
AUTHOR: ONG C N (Reprint); ONG H Y; CHUA L H
AUTHOR ADDRESS: DEP COMMUNITY MED, NATL UNIV SINGAPORE, NATL UNIV HOSP, KENT RIDGE, SINGAPORE 0511**SINGAPORE
JOURNAL: Analytical Biochemistry 173 (1): p64-69 1988
ISSN: 0003-2697
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: An ion chromatography (IC) method for the determination of copper and zinc in serum and whole blood is described. The sample treatment consists of diluting (2:3 for serum and 1:3 for whole blood) with 50% trichloroacetic acid, centrifuging, and dispensing the liquid directly into the chromatograph. The standard additions technique is used to establish the calibration. The close agreement between IC and spectrophotometric data on copper and zinc in serum and whole blood suggests that ion chromatography may be applied to complex biological matrices with minimal sample preparation.

6/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

08208677 BIOSIS NO.: 198682055064
A METHOD FOR THE ENZYMATIC IDENTIFICATION OF A URIC-ACID PEAK IN A LIQUID CHROMATOGRAM OF RAT SERUM MONITORED BY AN ELECTROCHEMICAL DETECTOR
AUTHOR: IWAMOTO T (Reprint); TOMIZAWA N; YOSHIURA M; KURIHARA S; IRIYAMA K
AUTHOR ADDRESS: DIV BIOCHEM, CENT RES LAB, JIKEI UNIV SCH MED, 3-25-8, NISH-SHINBASHI, MINATO-KU, TOKYO 105, JPN**JAPAN
JOURNAL: Jikeikai Medical Journal 33 (1): p11-16 1986
ISSN: 0021-6968
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Peak purity of uric acid in a liquid chromatogram of rat serum has been examined by the enzymatic treatment of the body fluid with uricase (EC 1.7.3.3). The enzyme catalyzes the conversion of uric

acid to allantoin. Eluate from a column was amperometrically monitored by aid of an electrochemical detector. Uric acid can be electrochemically oxidized under the chromatographic conditions used in this study, whereas allantoin cannot. The complete disappearance of a uric acid peak in a liquid chromatogram after the uricase treatment of rat serum indicates that the uric acid peak does not contain any other electroactive components. By using the enzymatic peak identification method, we have actually observed the complete disappearance of the uric acid peak in a liquid chromatogram of rat serum after the enzymatic treatment of the sample.

6/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06331007 BIOSIS NO.: 198172064958
LIQUID CHROMATOGRAPHIC ASSAY FOR METRONIDAZOLE AND TINIDAZOLE PHARMACO KINETIC AND METABOLIC STUDIES IN HUMAN SUBJECTS
AUTHOR: NILSSON-EHLE I (Reprint); URSING B; NILSSON-EHLE P
AUTHOR ADDRESS: DEP OF INFECTIOUS DISEASES, UNIV OF LUND, S-221 85 LUND, SWEDEN**SWEDEN
JOURNAL: Antimicrobial Agents and Chemotherapy 19 (5): p754-760 1981
ISSN: 0066-4804
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Methods were developed for measuring metronidazole, its 2 major metabolites and tinidazole in serum and urine. After treatment of each sample with an equal volume of 5% perchloric acid, the drugs were separated by reverse-phase high-pressure liquid chromatography (retention times, 6-18 min). Quantitatation was based on spectrometry at 320 nm. These assays were sensitive, rapid and specific and recoveries from biological samples were quantitative. Metronidazole and tinidazole were given as rapid i.v. infusions to 4 healthy human volunteers. The biological half-lives of these 2 compounds were 5.4 and 11.1 h, respectively. The hydroxy metabolite of metronidazole appeared quickly in serum and was eliminated at a slow rate. The acetic acid metabolite of metronidazole was detected in serum at very low levels and only for a limited time. No metabolic products of tinidazole were found in serum samples. In urine, 43.7% of the administered dose of metronidazole was recovered over a

period of 24 h (24.1% of the dose as the hydroxy metabolite, 12.0% as the acetic acid metabolite and 7.6% as unchanged drug). Only 18.4% of the infused dose of tinidazole was eliminated in urine over a period of 72 h and no metabolic products were detected.

6/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06287757 BIOSIS NO.: 198172021708
ISOZYMES OF RNASE IN HUMAN SERUM AND URINE 1. METHODOLOGY AND A SURVEY OF A CONTROL POPULATION
AUTHOR: THOMAS J M (Reprint); HODES M E
AUTHOR ADDRESS: DEP MED GENET, INDIANA UNIV SCH MED, INDIANAPOLIS, INDIANA 46223, USA**USA
JOURNAL: Clinica Chimica Acta 111 (2-3): p185-198 1981
ISSN: 0009-8981
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Methods are presented for the electrophoretic analysis of RNase enzymes in human serum and urine. Protocols for sample treatment, electrophoresis, and the RNase zymogram technique are described. With the application of these methods, RNase from serum and urine was separated into components differing on the basis of charge (charge isomers of isozymes), but not differing with respect to hydrolyzable sialic acid residues. Preliminary characterization of the electrophoretically separated components showed that some of the RNase species have different properties (pH optima and substrate preference). The major urine RNase isozymes appeared to be distinct from the major serum RNase isozymes. A survey of a control population indicated that the major serum and urine RNase enzymes are not genetically polymorphic.

6/7/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

05659775 BIOSIS NO.: 197967048770
ISO ENZYMES OF HUMAN PROSTATE ACID PHOSPHATASE
AUTHOR: CHU T M (Reprint); WANG M C; MERRIN C; VALENZUELLA L; MURPHY G P

AUTHOR ADDRESS: ROSWELL PARK MEML INST, 666 ELM ST, BUFFALO, NY 14263, USA
**USA
JOURNAL: Oncology (Basel) 35 (5): p198-200 1978
ISSN: 0030-2414
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: The isoenzymes of human prostatic acid phosphatase were studied by an isoelectric focusing technique. Purified acid phosphatase from malignant prostates contained 8 isoenzymes with pI 4.4-5.3. The sera from patients with prostate cancer had similar acid phosphatase isoenzyme patterns at pI 4.0-5.5; as the serum enzyme activities increased the pI of isoenzymes shifted to more acidic pH. These isoenzyme patterns of sera from patients with prostate cancer were different from those of patients with Gaucher's disease or from acid phosphatase of human erythrocytes, both of which exhibited only 1 enzyme band around pI [isoelectric point] 5.0 and 6.0, respectively. Treatment of serum sample of prostate cancer with neuraminidase did not result in a single enzyme band but altered the pI of isoenzymes, which shifted to a higher pH region. The significance of acid phosphatase activities and its isoenzyme patterns in prostate cancer merits further investigation.

6/7/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0001810747 BIOSIS NO.: 19674800094753
Effect of hydrogen peroxide on whey protein nitrogen value of heated skimmilk
AUTHOR: FISH NANCY L; MICKELSEN R
AUTHOR ADDRESS: Kans. State Univ., Manhattan, Kans., USA
JOURNAL: J DAIRY SCI 50 ((7)): p1045-1048 1967 1967
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Unspecified

ABSTRACT: The effect on the whey protein nitrogen value of skimmilk treated with different concentrations of hydrogen peroxide in the skimmilk 10 min. before it was heated at 85 degrees C for 30 min. was determined. Hydrogen peroxide decreased denaturation of skimmilk. Disc electrophoresis patterns were compared for normal, heated, hydrogen peroxide-heated and hydrogen peroxide-heated-catalase-treated samples of

[alpha]-lactalbumin, bovine serum albumin (BSA), [beta]-lactoglobulin and acid whey. The [alpha]-lactalbumin band was lighter in the hydrogen peroxide-treated sample than in the normal or heated sample. Bovine serum albumin was denatured by heat treatment. Hydrogen peroxide prevented total denaturation of BSA. [beta]-lactoglobulin was denatured by heat treatment and extensively modified by hydrogen peroxide. The electrophoretic pattern of hydrogen peroxide-heated acid whey had a darker band in the position normally occupied by [alpha]-lactalbumin. Hydrogen peroxide modified [beta]-lactoglobulin to form a band in the same position. A component not found in hydrogen peroxide-heated acid whey was in the electrophoretic pattern of acid whey from hydrogen peroxide-heated skimmilk, possibly from a reaction of hydrogen peroxide with a casein protein to form a product not precipitated with the casein. ABSTRACT AUTHORS: Authors

6/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0001491306 BIOSIS NO.: 19654600005397
Observations on the estimation of serum cholesterol using the ferric chloride reaction
AUTHOR: NAIR SHANTHA KUMARI; VENKATARAMAN A
AUTHOR ADDRESS: Haffkine Inst., Parel, Bombay, India
JOURNAL: IND J MED RES 52 ((4)): p381-391 1964 1964
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Unspecified

ABSTRACT: The direct treatment of the serum sample with the ferric chloride Reagent (Rosenthal's) results in extra chromogen which is quantitatively accounted for by the color produced by the precipitated proteins with the same reagent. Once the proteins are removed, the traces of aldehydic impurities in glacial acetic acid do not affect this reaction with cholesterol. Only tryptophane either as free amino acid or bound in proteins interferes with this reaction. Laboratory grade absolute alcohol is better than glacial acetic acid for precipitating the proteins and as solvent for the color development. Only micro quantities of blood samples are required and the whole procedure can be finished in 30 minutes. ABSTRACT AUTHORS: S. K. Nair

6/7/10 (Item 10 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

0001003256 BIOSIS NO.: 19593400000708
A simple method for determination of inorganic blood iodine
ORIGINAL LANGUAGE TITLE: Eine einfache Methode zur Bestimmung des anorganischen Blutjodes
AUTHOR: KLEIN ERICH
AUTHOR ADDRESS: Inneren Klin Krankenhauses, Stuttgart-Bad Canstatt, Germany
JOURNAL: BIOCHEM ZEITSCHR 326 ((1)): p9-13 1954 1954
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Unspecified

ABSTRACT: Inorganic serum iodine is determined as iodide in the supernate
after trichloroacetic acid treatment of the serum
sample. The method described is a modification of the cerous
sulfate-arsenite reaction for determining iodide. The method makes
possible determination of inorganic serum iodine as distinguished from
organic iodine contained in compounds removed from solution by
protein-precipitating agents. A comparison of results of analyses of sera
of 20 normal and 20 hyperthyroid subjects showed that the sera of the
hyperthyroid patients had an average of about twice as much inorganic
serum iodine as did the normal subjects. ABSTRACT AUTHORS: MDS
? ds

Set	Items	Description
S1	475	SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETEATMENT)
S2	146	RD S1 (unique items)
S3	117	S2 NOT PY>2006
S4	117	RD S3 (unique items)
S5	3720408	4 AND ACID
S6	24	S4 AND ACID

? s s6 and (immunoassay or antibody)

	24	S6
	475337	IMMUNOASSAY
	3552141	ANTIBODY
S7	3	S6 AND (IMMUNOASSAY OR ANTIBODY)

? t s7/7/all
>>>Format 7 is not valid in file 143

7/7/1 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

16170774 Genuine Article#: 142DL Number of References: 51

Title: Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection
Author: Hendrickson H (REPRINT) ; Laurenzana E; Owens SM
Corporate Source: Univ Arkansas Med Sci,Coll Pharm, Dept Pharmaceut Sci,4301 W Markham St 522-3/Little Rock//AR/72205 (REPRINT); Univ Arkansas Med Sci,Coll Pharm, Dept Pharmaceut Sci,Little Rock//AR/72205;
Coll Med,Dept Pharmacol & Toxicol,Little Rock//AR/
Journal: AAPS JOURNAL, 2006, V8, N4, PE709-E717
ISSN: 1550-7416 Publication Date: 20060000
Publisher: AMER ASSOC PHARMACEUTICAL SCIENTISTS, 2107 WILSON BLVD, STE 700,
ARLINGTON, VA 22201-3042 USA
Language: English Document Type: ARTICLE
Abstract: High-throughput liquid chromatography with tandem mass spectrometric detection (LC-MS/MS) methodology for the determination of methamphetamine (METH), amphetamine (AMP), 4-hydroxymethamphetamine (4-OH-METH), and 4-hydroxyamphetamine (4-OH-AMP) was developed and validated using simple trichloroacetic acid sample treatment. The method was validated in rat serum, brain, and testis. Lower limits-of-quantitation (LOQ) for METH and AMP were 1 ng center dot mL(-1) using positive ion electrospray tandem mass spectrometry (MS/MS). The accuracy of the method was within 25% of the actual values over a wide range of analyte concentrations. The within-assay precision was better than 12% (coefficient of variation).
The method was linear over a wide dynamic range (0.3-1000 ng center dot mL(-1)). Quantitation was possible in all 3 matrices using only serum standards because of minimal matrix-associated ion effects or the use of an internal standard. Finally, the LC-MS/MS method was used to determine serum, brain, and testis METH and AMP concentrations during a subcutaneous infusion (5.6 mg kg(-1) day(-1)) of METH in rats. Concentrations of 4-OH-AMP and 4-OH-METH were below the LOQ in experimental samples. The bias introduced by using serum calibrators for the determination of METH and AMP concentrations in testis and brain was less than 8% and insignificant relative to the interanimal variability.

7/7/2 (Item 1 from file: 305)

DIALOG(R)File 305:Analytical Abstracts

141424 AA Accession Number: 50-02-D-00246 DOC. TYPE: Journal
Sandwich enzyme immunoassay of total insulin in serum containing insulin antibodies.
AUTHOR: Tominaga, M.; Honda, M.; Itoh, Y.; Mokuda, O.; Ikeda, T.; Mashiba, H.
CORPORATE SOURCE: First Dept. Internal Med., Tottori Univ. Sch. Med., Yonago 683, Japan
JOURNAL: Clin. Chim. Acta, Volume: 169, Issue: 1, Page(s): 141
CODEN: CCATAR ISSN: 0009-8981
PUBLICATION DATE: Oct 1987 (871000) LANGUAGE: English
ABSTRACT: In the sandwich enzyme immunoassay described by Kohno et al. (Ibid., 1987, 163, 105) for total insulin (I) determination in serum containing endogenous antibodies to I, it was considered that the endogenous antibodies were inactivated by acid pre-treatment of the sample. I was determined with the insulin EIA kit (Mochida, Tokyo, Japan); dilution of the sample serum without acid treatment was adequate to avoid interference from the endogenous antibodies.

7/7/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

139336482 CA: 139(22)336482s PATENT
Diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
INVENTOR(AUTHOR): Coy, Johannes
LOCATION: Germany,
PATENT: European Pat. Appl. ; EP 1354961 A1 DATE: 20031022
APPLICATION: EP 20028831 (20020419)
PAGES: 28 pp. CODEN: EPXXDW LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12Q-001/68A
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR
SECTION:
CA214001 Mammalian Pathological Biochemistry
CA201XXX Pharmacology
CA203XXX Biochemical Genetics
IDENTIFIERS: diagnosis treatment proliferative abnormality human transketolase overexpression, cancer diagnosis therapy human transketolase overexpression

DESCRIPTORS:
Cell proliferation...
abnormal; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Lung,neoplasm...
adenocarcinoma, diagnosis and treatment of; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Antitumor agents...
antithiamine; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Luminescent substances...
bioluminescent, probe for diagnosis labeled with; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Diagnosis...
cancer; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Stomach,neoplasm...
carcinoma, diagnosis and treatment of; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Intestine,neoplasm...
colon, carcinoma, diagnosis and treatment of; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Intestine,neoplasm...
colon, diagnosis and treatment of; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Antibodies... Antitumor agents... Blood analysis... Drug screening... Epitopes... Human... Immunotherapy... Peptidomimetics... Primers(nucleic acid)... Probes(nucleic acid)... Urine analysis...
diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
Lung,neoplasm... Neoplasm... Pancreas,neoplasm... Stomach,neoplasm...
diagnosis and treatment of; diagnosis and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene

NASBA(nucleic acid sequence-based amplification)... Nucleic acid amplification(method)... Nucleic acid hybridization... PCR(polymerase chain
reaction)... Test kits...
    for diagnosis; diagnosis and treatment of proliferative abnormalities
    associated with overexpression of human transketolase like-1 gene
Antisense nucleic acids...
    for transketolase like-1 gene; diagnosis and treatment of proliferative
    abnormalities associated with overexpression of human transketolase like-1
    gene
Ribozymes...
    for transketolase like-1; diagnosis and treatment of proliferative
    abnormalities associated with overexpression of human transketolase like-1
    gene
Immunoassay...
    immunocytochem., for diagnosis; diagnosis and treatment of
    proliferative abnormalities associated with overexpression of human
    transketolase like-1 gene
Diagnosis...
    immunodiagnosis; diagnosis and treatment of proliferative abnormalities
    associated with overexpression of human transketolase like-1 gene
Nucleic acid hybridization...
    in situ, for diagnosis; diagnosis and treatment of proliferative
    abnormalities associated with overexpression of human transketolase like-1
    gene
Genetic methods...
    LCR (ligase chain reaction), for diagnosis; diagnosis and treatment of
    proliferative abnormalities associated with overexpression of human
    transketolase like-1 gene
Chelates... Chemiluminescent substances... Enzymes,biological studies...
Fluorescent substances... Radionuclides...
    probe for diagnosis labeled with; diagnosis and treatment of
    proliferative abnormalities associated with overexpression of human
    transketolase like-1 gene
PCR(polymerase chain reaction)...
    RT-PCR (reverse transcription-PCR), for diagnosis; diagnosis and
    treatment of proliferative abnormalities associated with overexpression of
    human transketolase like-1 gene
Animal cell... Animal tissue... Bile... Blood serum... Body fluid... Feces

```
... Semen...
    sample for diagnosis from; diagnosis and treatment of
proliferative
    abnormalities associated with overexpression of human
transketolase like-1
    gene
Nucleic acids... Peptides,biological studies...
    sample for diagnosis; diagnosis and treatment of proliferative
    abnormalities associated with overexpression of human
transketolase like-1
    gene
Gene,animal...
    TKT-L1; diagnosis and treatment of proliferative abnormalities
associated
    with overexpression of human transketolase like-1 gene
Immunization...
    vaccination; diagnosis and treatment of proliferative
abnormalities
    associated with overexpression of human transketolase like-1 gene
  CAS REGISTRY NUMBERS:
9014-48-6  -like; diagnosis and treatment of proliferative
abnormalities
    associated with overexpression of human transketolase like-1 gene
174944-79-7  diagnosis and treatment of proliferative abnormalities
associated
    with overexpression of human transketolase like-1 gene
615290-51-2  615290-52-3  615290-53-4  615290-54-5  primer; diagnosis
and
    treatment of proliferative abnormalities associated with
overexpression of
    human transketolase like-1 gene
615290-50-1  probe; diagnosis and treatment of proliferative
abnormalities
    associated with overexpression of human transketolase like-1 gene
? ds

Set     Items   Description
S1        475   SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETEATMENT)
S2        146   RD S1  (unique items)
S3        117   S2 NOT PY>2006
S4        117   RD S3  (unique items)
S5    3720408   4 AND ACID
S6         24   S4 AND ACID
S7          3   S6 AND (IMMUNOASSAY OR ANTIBODY)
? s adiponectin
      S8   55814  ADIPONECTIN
? s s8 and (assay or immunoassy)
           55814  S8
         3689188  ASSAY
             196  IMMUNOASSY
      S9    3402  S8 AND (ASSAY OR IMMUNOASSY)
? s s9 not PY>2006
```

```
            3402  S9
        22778661  PY>2006
     S10    1185  S9 NOT PY>2006
? rd s10

>>>Duplicate detection is not supported for File 393.

>>>Records from unsupported files will be retained in the RD set.
     S11     352  RD S10  (unique items)
? t s11/7/1-10
>>>Format 7 is not valid in file 143

 11/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019986882   BIOSIS NO.: 200800033821
Adiponectin in early and chronic rheumatoid arthritis and
  osteoarthritis
AUTHOR: Laurberg T (Reprint); Ellingsen T; Frystyk J; Hansen I;
Jorgensen A
  ; Tarp U; Hetland M; Horslev-Petersen K; Homung N; Poulsen J;
Flyvbjerg A
  ; Stengaard-Pedersen K
AUTHOR ADDRESS: Hvidovre Univ Hosp, Clin Rheumatol, DK-2650 Hvidovre,
  Denmark**Denmark
JOURNAL: Annals of the Rheumatic Diseases  65 (Suppl. 2): p307-308
JUL 2006
 2006
CONFERENCE/MEETING: Annual European Congress of Rheumatology (EULAR
2006)
Amsterdam, NETHERLANDS  June 21 -24, 2006; 20060621
ISSN: 0003-4967
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Citation
LANGUAGE: English


 11/7/2     (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019698701   BIOSIS NO.: 200700358442
Globular adiponectin augments from pancreatic islet beta cells at
  insulin secretion high glucose concentrations
AUTHOR: Gu Weiqiong; Li Xiaoying; Liu Changqin; Yang Jun; Ye Lei; Tang
  Jingfen; Gu Yuanjun; Yang Yisheng; Hong Jie; Zhang Yifei; Chen
Mingdao;
  Ning Guang (Reprint)
AUTHOR ADDRESS: Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp,Dept
  Endocrinol and Metab, Shanghai Clin Ctr Endocrine and Metab Dis,
Ruijin
```

2nd Rd, Shanghai 200025, Peoples R China**Peoples R China
AUTHOR E-MAIL ADDRESS: guangning@medmail.com.cn
JOURNAL: Endocrine 30 (2): p217-221 OCT 2006 2006
ISSN: 0969-711X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Adiponectin plays an important role in improving insulin resistance and preventing atherosclerosis. However it has been rarely reported that adiponectin influences insulin secretion because its receptor was identified in human islet P cells. In order to investigate the direct effect of adiponectin on pancreatic islet 0 cells, we performed an insulin secretion test in purified rat islets, which were incubated with adiponectin (100 ng/mL) at low (3.3 mA4) and high (16.7 mM) glucose concentrations. Furthermore, cell lysates were extracted from the adiponectin-treated islets for p-AMPK alpha assay. RTPCR and immunohistochemical examination showed both adiponectin receptor 1 (AdipoR1) and receptor 2 (AdipoR2) were expressed in islet cells and AdipoR1 was predominantly expressed. Insulin secretion was significantly increased in the presence of adiponectin for 6 h at high glucose concentration. Meanwhile, the levels of phosphorylated AMPK increased with adiponectin treatment at high glucose concentrations. It is concluded that adiponectin augments insulin secretion from pancreatic islet P cells at high glucose concentration through AMPK activation.

11/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0019678755 BIOSIS NO.: 200700338496
Effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase activity in human umbilical vein endothelial cells
AUTHOR: Li Bing-rong; Zheng Dan; Deng Hua-cong (Reprint); Liu Jin-bo; Lan Li-zhen; Zheng Hong-ting
AUTHOR ADDRESS: Chongqing Univ Med Sci, Affiliated Hosp 1, Dept Endocrinol, Chongqing 400016, Peoples R China**Peoples R China
AUTHOR E-MAIL ADDRESS: denghuacong@yahoo.com.cn
JOURNAL: Zhonghua Xinxueguanbing Zazhi 34 (12): p1122-1125 DEC 2006 2006

ISSN: 0253-3758
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Chinese

ABSTRACT: Objective To evaluate the effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase (NOS) activity in human umbilical vein endothelial cells HUVECs). Methods Protein expression of apM1 in cell culture supernatant of HUVECs transfected with human Ad-apM1 was detected by double antibody sandwich ELISA. The effect of human adiponectin on cell proliferation was assessed by MTT assay. The total NOS and iNOS expressions were measured by chromatometry. Results Human adiponectin protein level and total NOS and eNOS expressions were significant increased and iNOS expression significantly reduced in culture supernatant of HUVECs infected with Ad-apM1 compared to that in control HUVECs. The recombinant adenovirus had no influence on HUVECs growth as determined by WITT assay. Conclusions Human Ad-apM1 can he effectively expressed in HUVECs and do not influence HUVECs growth. Increased total NOS and eNOS expressions and decreased iNOS expression in HUVECs transfected with Ad-apM1 gene suggest a potential role of Ad-apM1 gene transfer for the prevention and treatment of arteriosclerosis.

11/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0019605892 BIOSIS NO.: 200700265633
Elevated plasma HDL-cholesterol levels by CETP gene polymorphism and atherosclerosis; The J-SHIPP study
AUTHOR: Haiyan Guo (Reprint); Tabara Yasuharu; Kawamoto Ryuichi; Tachibana-Iimori Rieko; Yamamoto Miyuki; Nakura Jun; Miki Tetsuro; Kohara Katsuhiko
AUTHOR ADDRESS: Ehime Univ, Sch Med, Dept Geriatr Med, Matsuyama, Ehime 790, Japan**Japan
AUTHOR E-MAIL ADDRESS: tabara@m.ehime-u.ac.jp
JOURNAL: Journal of Hypertension 24 (Suppl. 6): p279 DEC 2006 2006
CONFERENCE/MEETING: 21st Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension Fukuoka, JAPAN October 15 -19, 2006;

20061015
SPONSOR: Int Soc Hypertens
Japanese Soc Hypertens
ISSN: 0263-6352
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Citation
LANGUAGE: English

11/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0019598281 BIOSIS NO.: 200700258022
Adiponectin produced by lymphocytes inhibits granulopoiesis.
AUTHOR: Crawford Lisa J (Reprint); Peake Roy W; Price Susan; Morris Treen C
; Irvine Alexandra E
AUTHOR ADDRESS: Queens Univ Belfast, Belfast, Antrim, UK**UK
JOURNAL: Blood 108 (11, Part 1): p374A NOV 16 2006 2006
CONFERENCE/MEETING: 48th Annual Meeting of the American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006;
20061209
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Previous studies by our group have shown that normal unstimulated
lymphocytes produce a protein which inhibits colony formation
ofgranulopoietic progenitors, but has no effect on erythroid progenitors.
Therefore, this inhibitor was initially designated GIA (granulopoietic
inhibitory activity). GIA was identified as a glycoprotein of
approximately 30 kDa, with a pl of 7.9 - 8.4. Futhermore, we demonstrated
that this inhibitor may have physiological significance in that its
production is altered in patients with neutropenia. GIA has proved
difficult to characterise to date since it is produced in relatively low
amounts although it has a high specific biological activity.
Adiponectin is an adipokine reported to share many of the
inhibitory characteristics of GIA and has been demonstrated to act as a
negative regulator of hematopoiesis and immune response. This study aimed
to determine whether GIA is adiponectin or if it represents an
adiponectin-like molecule. Lymphocyte conditioned medium (LCM) from

lymhocytes cultured at I X 10(6) cells/ml in HL- I minimal medium was used as a source of GIA. Inclusion of LCM as 10% of the top layer of agar in a myeloid colony assay inhibited growth of CFU-GM by 52 11 % (n=3), confirming the presence of the inhibitory activity. RNA and protein from lymphocytes and LCM harvested over a 7 day culture period were subsequently investigated for adiponectin expression. Western blot analysis demonstrated a distinct banding pattern in days 3-7 LCM corresponding to monomers, dimers, trimers and greater. This is consistent with adiponectin which circulates as a multimer of trimers. Characterisation of GIA at the transcript level confirmed that GIA is in fact adiponectin. The N-terminal collagenous domain, C terminal globular domain and full length adiponectin were amplified by RT-PCR analysis. Adiponectin is thought to be secreted exclusively from adipocytes and much of our current knowledge of this molecule relates to its metabolic functions. Our study provides evidence that adiponectin is also produced by lymphocytes and may play a role in the pathogenesis of neutropenia.

11/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0019511228 BIOSIS NO.: 200700170969
Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses
AUTHOR: Hashimoto Naotake (Reprint); Kanda Junji; Nakamura Tomonori; Horie Atsuya; Kurosawa Hiroko; Hashimoto Toru; Sato Kazutoshi; Kushida Syunichi ; Suzuki Masaru; Yano Shingo; Iwai Rie; Takahashi Hidenori; Yoshida Shouji
AUTHOR ADDRESS: Asahi Gen Hosp, Dept Diabet and Metab Dis and Internal Med, Chiba 2892511, Japan**Japan
AUTHOR E-MAIL ADDRESS: naohasi@hospital.asahi.chiba.jp
JOURNAL: Metabolism Clinical and Experimental 55 (12): p1653-1657 DEC 2006
2006
ISSN: 0026-0495
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Adiponectin influences insulin sensitivity and lipid

oxidation. Because low plasma adiponectin concentrations are suspected to promote atherosclerosis, we retrospectively assessed relationships of plasma adiponectin concentration to characteristics of coronary heart disease (CHID). Japanese men undergoing coronary angiography for CHD (n = 139) were grouped according to serum adiponectin concentration by enzyme-linked immunosorbent assay (low, < 4.0; medium, 4.0-8; high, > 8.0 mu g/mL). Numbers of coronary arteries with at least 50% stenosis were determined. Serum adiponectin concentration correlated positively with age at onset of CHD (r = 0.285, P = .003). Age at CHD onset in the low-adinopectin group was younger than in the medium or high groups. Adiponectin was protective against CHD onset at ages younger than 58 years (relative risk, 0.778; P = .0047). Significantly more arteries were affected in low-adiponectin patients than in the medium or high group (each P < .01). Adiponectin concentration correlated positively with high-density lipoprotein cholesterol concentration and negatively with triglyceride concentration. Only in diabetic patients did serum adiponectin concentration correlate negatively with body mass index. Low plasma adiponectin concentrations were associated with early CHD onset and multiple atherosclerotic lesions in coronary arteries. Thus, adiponectin concentrations may influence risk of CHD and might serve as one of the screening tests facilitating early intervention.

11/7/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0019511227 BIOSIS NO.: 200700170968
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy
AUTHOR: Matsumoto Sachiko; Takebayashi Kohzo (Reprint); Aso Yoshimasa
AUTHOR ADDRESS: Dokkyo Univ, Dept Internal Med, Koshigaya 3438555, Japan**
Japan
AUTHOR E-MAIL ADDRESS: takeb@gmail.plala.or.jp
JOURNAL: Metabolism Clinical and Experimental 55 (12): p1645-1652 DEC 2006
2006
ISSN: 0026-0495
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Angiotensin II can influence adipocytokine levels in adipose tissue, but the association between aldosterone, which mediates the effect of angiotensin II, and adipocytokines has yet to be fully elucidated. This study was designed to investigate the effect of spironolactone, a representative aldosterone blocker, on adipocytokines such as adiponectin, visfatin, plasminogen activator inhibitor (PAI)-I and tumor necrosis factor alpha in patients with type 2 diabetic nephropathy: the study included 33 patients, 22 of whom were randomly assigned to the spironolactone (50 mg/d) group and 11 to the amlodipine (2.5 mg/d) group. Data were collected at baseline and after 3 months of treatment and compared with baseline data for 25 age-matched healthy subjects. A significant decrease in plasminogen activator inhibitor 1 in the spironolactone group was observed (22.6 +/- 13.4 to 19.2 +/- 11.3 ng/mL, P = .0323), but this did not occur in the amlodipine group. Adiponectin and visfatin levels did not change in the spironolactone and amlodipine groups, but significant increases in these adipocytokines were found in a subgroup of patients in the spironolactone group with glycated hemoglobin A(1c) (HbA(1c)) 8.0% or greater (11.8 +/- 6.4 to 13.3 +/- 7.4 mu g/mL, P = .0344; and 1.39 +/- 0.92 to 2.26 +/- 0.76 ng/mL, P = .0397, respectively). The tumor necrosis factor alpha level at baseline exceeded the lower detection limit of the assay in only 6 patients in the spironolactone group, and no change occurred in these patients. Moreover, neither spironolactone nor amlodipine therapy caused a change in high-sensitivity C-reactive protein or soluble CD40 ligand, but a significant decrease in the level of brain natriuretic peptide was found in the spironolactone group only. Furthermore, significant increases of HbA(1c), creatinine, potassium, and aldosterone levels and plasma renin activity, and a decrease in urinary albumin excretion were also observed only in the spironolactone group. The number of patients with HbA(1c) 8.0% or greater increased after spironolactone treatment. A significant decrease in systolic but not in diastolic blood pressure was observed in both treatment groups. In conclusion, our data

suggest that in patients with type 2 diabetes mellitus complicated by diabetic nephropathy, spironolactone can decrease plasminogen activator inhibitor 1 and brain natriuretic peptide levels in addition to urinary albumin excretion, and systolic blood pressure, and that in patients with poor glycemic control, spironolactone can increase the levels of adiponectin and visfatin. However, the significant elevation of HbA(1c) levels by spironolactone should be emphasized.

11/7/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0019493026 BIOSIS NO.: 200700152767
Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance
AUTHOR: Nilsson Peter M (Reprint); Engstrom Gunnar; Hedblad Bo; Frystyk Jan ; Persson Margaretha M; Berglund Goran; Flyvbjerg Allan
AUTHOR ADDRESS: Lund Univ, Malmo Univ Hosp, Dept Clin Sci Med, S-20502 Malmo, Sweden**Sweden
AUTHOR E-MAIL ADDRESS: Peter.Nilsson@med.lu.se
JOURNAL: Arteriosclerosis Thrombosis and Vascular Biology 26 (12): p 2758-2762 DEC 2006 2006
ISSN: 1079-5642
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background - Circulating adiponectin is a marker for insulin sensitivity, derived from fat cells. It is largely unknown if adiponectin is also an independent marker for early atherosclerosis.Methods and Results - Plasma adiponectin levels were measured in 373 men and 514 women of middle-age by a time-resolved immunofluorometric assay. The subjects were sampled stratified for degree of insulin sensitivity (HOMA-IR). An ultrasound measurement of the right common carotid artery intima media thickness (IMT) was made. When the distribution of adiponectin was stratified into sex-specific quartiles (Q1 to Q4), men in Q4 differed from Q1 in higher mean age and high-density lipoprotein (HDL) cholesterol, but lower blood pressure,

HbA(1c), HOMA-index, and body mass index. Women showed similar associations. Mean IMT for men was significantly lower (P = 0.03) in adiponectin Q4 as compared with Q1 when adjusted for age, waist, smoking, HDL cholesterol, and diastolic blood pressure. When adding HbA1c and HOMA to the model, the association was no longer significant (P = 0.15). In women no difference in IMT was noticed across adiponectin quartiles.Conclusion - Plasma adiponectin is a marker of glucose metabolism and obesity and shows an inverse age-adjusted association with carotid ultrasound IMT in men, but not in women. This association is attenuated after adjustments for other risk factors.

11/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0019464349 BIOSIS NO.: 200700124090
Role of adiponectin and its relationship to procollagen type I carboxy-terminal propeptide in essential hypertension
AUTHOR: Tsai Wei-Chuan (Reprint); Lin Chih-Chan; Lee Cheng-Han; Li Wei-Ting ; Chen Ju-Yi; Chen Jyh-Hong
AUTHOR ADDRESS: Natl Cheng Kung Univ, Med Ctr, Tainan 70101, Taiwan**Taiwan
JOURNAL: Circulation 114 (18, Suppl. S): p773-774 OCT 31 2006 2006
CONFERENCE/MEETING: 79th Annual Scientific Session of the American-Heart-Association Chicago, IL, USA November 12 -15, 2006; 20061112
SPONSOR: Amer Heart Assoc
ISSN: 0009-7322
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background: Serum concentration of procollagen type I carboxy-terminal propeptide (PICP) is proved to be a good marker for myocardial fibrosis in hypertension. Adiponectin is a cytokine from adipose tissue and decreased adiponectin level is associated with increased atherosclerosis. However, the role of adiponectin and its relationship to PICP in essential hypertension have never been studied before. Methods: This study consisted of 188 non-diabetic essential hypertensive patients (mean age 41 +/- 7 years, 128 men). All of the patients did not have vascular complications; renal, or liver diseases.
Serum concentrations of PICP and adiponectin were measured by enzyme-linked immunosorbent assay. Pulse wave velocity (PWV) assessed by tonometry was used as an index for aortic stiffness. Results:

Adiponectin was significantly correlated with triglyceride (r = -243, p = 0.001), high-density lipoprotein (r = 0.284, p <0.001), insulin (r = -0.169, p = 0.020), and body mass index (r = -0.208, p = 0.004). PICP was significantly correlated with PWV (r = 0.146, p = 0.047). PICP was not correlated with blood pressure, lipid profiles, body mass index, and insulin level. However, PICP was significantly correlated with adiponectin (r = -0.200, p = 0.006). After multivariate analysis, PICP was still significantly correlated with adiponectin (B = -0.220, p 0.004). Conclusions: Serum adiponectin levels could be a marker for metabolic syndrome in essential hypertension. Adiponectin was significantly negatively correlated with PICP. Adiponectin probably plays an important role in myocardial fibrosis as well as aortic stiffness in essential hypertension.

11/7/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0019462349 BIOSIS NO.: 200700122090
Adipokine resistin induces expression of adhesion molecules and tissue factor in human coronary artery endothelial cells
AUTHOR: Calabro Paolo (Reprint); Cirillo Plinio; Maddaloni Valeria; Limongelli Giuseppe; Weisz Sara; Rucco Maria Antonietta; Palmieri Rosalinda; Riegler Lucia; De Palma Raffaele; Chiarillo Massimo; Golino Paolo; Calabro Raffaelle
AUTHOR ADDRESS: Second Univ Naples, Monaldi Hosp, Div Cardiol, Naples, Italy**Italy
JOURNAL: Circulation 114 (18, Suppl. S): p308 OCT 31 2006 2006
CONFERENCE/MEETING: 79th Annual Scientific Session of the American-Heart-Association Chicago, IL, USA November 12 -15, 2006; 20061112
SPONSOR: Amer Heart Assoc
ISSN: 0009-7322
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Objective: Atherosclerosis is characterized by endothelial inflammation and dysfunction. Adipose tissue has been increasingly recognized as an active endocrine organ secreting so-called adipokines, and among them resistin is probably the latest described and the less studied. Resistin has been defined as a novel inflammatory marker in atherosclerosis and its serum levels correlate With coronary artery calcification and multivessel coronary artery disease. The

pathophysiology underlying this interplay, however, remains incompletely characterized. The aim of our study is to determine whether resistin might affect the prothrombotic and atherosclerotic characteristics of human coronary artery endothelial cells. Methods and Results: Incubation of endothelial cells with resistin led to an upregulation of the expression of both ICAM-1 and VCAM-1 (CAMS) as demonstrated by FACS analysis. Moreover, tissue factor (TF) expression and activity were also induced in a dose dependent manner, as shown by FACS analysis and real time PCR, and a specific colorimetric assay respectively. To better investigate the intracellular mechanisms, activation of the transcription factor, NF-kB, was demonstrated by EMSA and by suppression of CAMS and TF expression by the NF-kB inhibitor, pyrrolidine-dithio-carbamate ammonium. Conclusions: these data confirm that resistin may contribute to atherothrombosis exerting direct effects on human coronary endothelial cells by promoting CAMs and TF expression, supporting the notion that resistin, besides representing a marker of inflammation, is an effector molecule able to induce a pro-atherothrombotic phenotype in cells of the vessel wall.[GRAPHICS]ssion was not enhanced along with the increase of adiponectin levels. Moreover, pretreatment with a PI3 kinase inhibitor wortmannin, but not a PPAR gamma antagonist GW9662, significantly inhibited the IL-10-induced adponectin production. In contrast, IL-10 did not alter leptin and TNF-alpha(levels compared to controls (238.4 +/- 8.6 vs.. 223.1 +/- 0.8 pg/ml, 396.8 +/- 18.2 vs. 407.0 +/- 21.8 pg/ml, respectively). Conclusion: IL-10 enhanced adiponectin production and PPAR gamma expression without promoting adipogenic differentiation in visceral SVCs. These results suggest the potential for therapeutic use of IL-10 in metabolic syndrome.

? ds

Set	Items	Description
S1	475	SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETEATMENT)
S2	146	RD S1 (unique items)
S3	117	S2 NOT PY>2006
S4	117	RD S3 (unique items)
S5	3720408	4 AND ACID
S6	24	S4 AND ACID
S7	3	S6 AND (IMMUNOASSAY OR ANTIBODY)

```
S8      55814   ADIPONECTIN
S9       3402   S8 AND (ASSAY OR IMMUNOASSY)
S10      1185   S9 NOT PY>2006
S11       352   RD S10  (unique items)
? s adiponectin 5n immunoassay
     S12       0  ADIPONECTIN 5N IMMUNOASSAY
? s adiponectin 10n immunoassay
     S13       0  ADIPONECTIN 10N IMMUNOASSAY
? s adiponectin and immunoassay
           55814  ADIPONECTIN
          475337  IMMUNOASSAY
     S14     510  ADIPONECTIN AND IMMUNOASSAY
? s s11 and s14
             352  S11
             510  S14
     S15      27  S11 AND S14
? rd s15

>>>Duplicate detection is not supported for File 393.

>>>Records from unsupported files will be retained in the RD set.
     S16      27  RD S15  (unique items)
? t s16/7/all
>>>Format 7 is not valid in file 143

 16/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

19193655   BIOSIS NO.: 200600539050
Determination of adiponectin in serum using a latex particle-enhanced
  turbidimbtric immunoassay with an automated analyzer
AUTHOR: Nishimura Ayako; Sawai Tokio (Reprint)
AUTHOR ADDRESS: Mitsubishi Kagaku Iatron Inc, Div Res and Dev, 1460-6
  Mitodai, Takomachi, Chiba 2892247, Japan**Japan
AUTHOR E-MAIL ADDRESS: sawai.tokio@me.mk-iatron.co.jp
JOURNAL: Clinica Chimica Acta  371 (1-2): p163-168 SEP 2006 2006
ISSN: 0009-8981
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background: Adiponectin is an adipose-derived hormone that
  plays a role in regulating metabolic processes such as fat
partitioning
  and lipid and glucose metabolism. Quantification of adiponectin is
  useful for obtaining information on metabolic syndrome, but there
is no
  rapid method to measure adiponectin for clinical use.Methods: We
  developed a rapid and sensitive latex particle-enhanced
turbidimetric
  immunoassay (LTIA) using a latex bead-immobilized anti-
```

adiponectin polyclonal antibody. The assay was performed on a Hitachi H7170 analyzer and evaluated for validity as a method to quantitate adiponectin, in parallel with the ELISA.Results: Dilution tests using LTIA showed linearity from 0.25 to 30 mu g/ml. Within-run CV and total CV were obtained in the range of 0.8-1.9% and 1.1-2.0%, respectively. No interference was observed in the testing of specimens containing potentially interfering substances such as bilirubin, ditaurobilirubin, hemoglobin triglyceride, rheumatoid factor, type IV collagen, fibronectin, and complement factor (Clq). A strong correlation between LTIA and ELISA was confirmed (n=30, r=0.990, y=0.95x+0.39).Conclusion: The LTIA assay is applicable to quantitating the serum concentration of adiponectin. This assay is more convenient and faster than ELISA and suitable for clinical routine analysis. (c) 2006 Elsevier B.V. All rights reserved.

16/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

19120920 BIOSIS NO.: 200600466315
Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25)
AUTHOR: Lopez-Bermejo Abel (Reprint); Khosravi Javad; Fernandez-Real Jose Manuel; Hwa Vivian; Pratt Katherine L; Casamitjana Roser; Garcia-Gill Maria M; Rosenfeld Ron G; Ricart Wifredo
AUTHOR ADDRESS: Dr Josep Trueta Hosp, Unit Diabet Endocrinol and Nutr, Av Francia S-N, Girona 17007, Spain**Spain
AUTHOR E-MAIL ADDRESS: uden.alopez@htrueta.scs.es
JOURNAL: Diabetes 55 (8): p2333-2339 AUG 2006 2006
ISSN: 0012-1797
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: IGF-binding protein (IGFBP)-related protein 1 (IGFBP-rP1) has been shown to bind both IGFs and insulin, albeit with low affinity, and to inhibit insulin signaling. We hypothesized that IGFBP-rP1 is associated with insulin resistance and components of the IGF system in humans. To this aim, a cross-sectional study was conducted in 113 nondiabetic and 43 type 2 diabetic men. Insulin sensitivity (insulin sensitivity index [Si] from intravenous glucose tolerance tests in

nondiabetic subjects, or the rate constant for disappearance of glucose [K-ITT] from insulin tolerance tests in type 2 diabetic subjects), circulating IGFBP-rP1 (from enzyme-linked immunosorbent assay), adiponectin (from radioimmunoassay), C-reactive protein (CRP; from immunoturbidimetry), soluble tumor necrosis factor receptor 2 (sTNFR2; from enzyme-amplified sensitivity immunoassay), and IGF system parameters (IGF-I, free IGF-I, and IGFBP-1 from immunoradiometric assay) were assessed in all subjects. Among nondiabetic men, those in the highest quartile for circulating IGFBP-rP1 exhibited decreased S-i and adiponectin (both P < 0.01) as well as increased CRP and sTNFR2 (both P < 0.05). Circulating IGFBP-rP1 was also found to be increased in previously undiagnosed type 2 diabetic patients (P = 0.01) but not in known type 2 diabetic patients receiving pharmacological therapy. Although no changes in IGF system components were evident by IGFBP-rP1 quartiles in nondiabetic subjects, independent positive associations of IGFBP-rP1 with circulating fasting IGFBP-1 were evident after adjustment for insulin resistance parameters in both nondiabetic and type 2 diabetic subjects, with IGFBP-rP1 explaining 2 and 11% of IGFBP-1 variance, respectively. In additional multivariate analyses, S-i, sTNFR2, and age stood as independent predictive variables of IGFBP-rP1 (together explaining 18% of its variance) in nondiabetic subjects, and BMI became the only independent predictive variable of IGFBP-rP1 (explaining 26% of its variance) in type 2 diabetic men. These findings show for the first time that circulating IGFBP-rP1 is increased with insulin resistance, and they also suggest novel interactions between IGFBP-rP1 and the IGF system in humans.

16/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

18992081 BIOSIS NO.: 200600337476
Preliminary investigation of blood correlates of change in adiponectin with change in body fat
AUTHOR: Wright Jennifer Anne (Reprint); May Melissa; Cussler Ellen; Lohman

Timothy; Thompson Patricia
AUTHOR ADDRESS: Univ Arizona, Tucson, AZ 85721 USA**USA
JOURNAL: FASEB Journal 20 (5, Part 2): pA1171 MAR 7 2006 2006
CONFERENCE/MEETING: Experimental Biology 2006 Meeting San Francisco, CA,
USA April 01 -05, 2006; 20060401
SPONSOR: Amer Assoc Anatomists
Amer Physiol Soc
Amer Soc Biochem & Mol Biol
Amer Soc Investigat Pathol
Amer Soc Nutr
Amer Soc Pharmacol & Expt Therapeut
ISSN: 0892-6638
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Changes in adiponectin have been associated with change in percent total body fat (%TBF), however, the relationship between estrogen and adiponectin with fat change, has not been well defined. Since elevated adiponectin is associated with diabetes risk reduction, its interaction with estrogen may be important to postmenopausal (PM) women. Therefore, a preliminary analysis of the relationship between estrogen and adiponectin was per-formed in the greatest %TBF losers (-6.8%, N=9) and gainers (4.7%, N=11) of a large randomized controlled trial of resistance training in PM women, using or not using hormone therapy. Serum estrogen and plasma adiponectin were measured by radio immunoassay and enzyme-linked immunosorbent assay, respectively. TBF was assessed by dual-energy X-ray absorptiometry. There were no significant differences between groups at baseline. Gainers of %TBF significantly decreased adiponectin in 1 year, compared to losers ($p < 0.03$). Multiple linear regression demonstrated a significant independent negative association between change in adiponectin and change in %TBF ($p<0.01$) and, unexpectedly, an independent, positive association with change in estradiol ($p<0.03$) and estrone ($p<0.06$). Based on this small sample, we conclude that there may be a relationship between adiponectin and hormone levels in PM women warranting further investigation.

15502784 Genuine Article#: 076YZ Number of References: 26

Title: Roles of adipocyte derived hormone adiponectin and resistin in insulin resistance of type 2 diabetes
Author: Lu HL; Wang HW (REPRINT) ; Wen Y; Zhang MX; Lin HH
Author Email Address: hwwang@tjh.tjmu.edu.cn
Corporate Source: Huazhong Univ Sci & Technol,Dept Pediat, Tongji Hosp, Tongji Med Coll,Wuhan 430030/Hubei Province/Peoples R China/ (REPRINT); Huazhong Univ Sci & Technol,Dept Pediat, Tongji Hosp, Tongji Med Coll,Wuhan 430030/Hubei Province/Peoples R China/; Huazhong Univ Sci & Technol,Dept Endocrinol, Tongji Hosp, Tongji Med Coll,Wuhan 430030/Hubei Province/Peoples R China/
Journal: WORLD JOURNAL OF GASTROENTEROLOGY, 2006, V12, N11 (MAR 21), P 1747-1751
ISSN: 1007-9327 Publication Date: 20060321
Publisher: W J G PRESS, PO BOX 2345, BEIJING 100023, PEOPLES R CHINA
Language: English Document Type: ARTICLE
Abstract: AIM: To detect plasma levels of new adipocyte derived hormone adiponectin and resistin in type 2 diabetes patients and to explore their potential roles in insulin resistance in type 2 diabetes.

METHODS: According to the body mass index (BMI), 60 type 2 diabetes patients were divided into two groups, one group was non-obese diabetes patients with BMI < 25Kg/M-2 (30 cases) and the other group was obese diabetes patients with BMI > 25Kg/M-2 (30 cases). There were 28 healthy persons in the control group. ELISA technique was employed to determine the plasma adiponectin and resistin concentrations. The fasting blood glucose, insulin and blood lipid were detected respectively by electrocheminescence immunoassay and immunoturbidimetric assay. Insulin resistance index and insulin sensitive index were calculated by the homeostasis model assessment (HOMO).

RESULTS: The levels of plasma adiponectin were decreased significantly in diabetes group compared to that in control group (non-obese: 8.58 +/- 0.86, obese: 6.22 +/- 1.34 vs 10.53 +/- 1.47 P < 0.05); moreover, adiponectin concentration in obese diabetes group was significantly decreased compared to that in non-obese diabetes group (6.22 +/- 1.34 vs 8.58 +/- 0.86, P < 0.05). The levels of plasma resistin were increased significantly in diabetes group compared to that in control group (obese: 18.64 4.65, non-obese: 24.05

+/- 9.07 vs 14.16 +/- 5.25, P < 0.05, P < 0.05); furthermore, the levels of resistin in obese diabetes group were increased significantly compared to that in non-obese diabetes group (P < 0.05). Plasma adiponectin was correlated negatively with BMI, blood glucose, insulin resistance index and triglyceride (respectively, r = -0.55, P < 0.01; r=-0.51, P < 0.05; r = -0.52, P < 0.05; r = -0.39, P < 0.05), while it was positively correlated with insulin sensitive index (r = 0.45, P < 0.05). Conversely, plasma resistin correlated positively with BMI, blood glucose, triglyceride and insulin resistance index (respectively, r = 0.40, P < 0.05; r=0.52, P < 0.05; r = 0.46, P < 0.01; r = 0.27, P < 0.05), and negatively correlated with insulin sensitive index (r = -0.32, P < 0.05).

CONCLUSION: Plasma adiponectin and resistin are associated with the disorder of metabolism of glucose and lipid in diabetes. The relationship between these hormone and insulin sensitivity suggests that they may take part in the development of insulin resistance of type 2 diabetes.

16/7/5 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE

0006718506 SUPPLIER NUMBER: 2006219914
Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer
Nishimura A.; Sawai T.
AUTHOR EMAIL: sawai.tokio@me.mk-iatron.co.jp
CORRESP. AUTHOR/AFFIL: Sawai T., Division of Research, Development Mitsubishi Kagaku Iatron Inc., 1460-6 Mitodai, Tako-machi, Katori-gun, Chiba-ken, 289-2247, Japan
CORRESP. AUTHOR EMAIL: sawai.tokio@me.mk-iatron.co.jp
Journal: Clinica Chimica Acta (Clin. Chim. Acta), v371, n1-2, (163-168), 2006, Netherlands
PUBLICATION DATE: September 1, 2006 (20060901)
CODEN: CCATA
ISSN: 0009-8981 eISSN: 1097-0169
DOI: http://dx.doi.org/10.1016/j.cca.2006.03.008
PUBLISHER ITEM IDENTIFIER: S0009898106001641
RECORD TYPE: Abstract; New
DOCUMENT TYPE: Article

LANGUAGES: English SUMMARY LANGUAGES: English
NO. OF REFERENCES: 24
Background: Adiponectin is an adipose-derived hormone that plays a role in regulating metabolic processes such as fat partitioning and lipid
and glucose metabolism. Quantification of adiponectin is useful for obtaining information on metabolic syndrome, but there is no rapid method
to measure adiponectin for clinical use. Methods: We developed a rapid and sensitive latex particle-enhanced turbidimetric immunoassay (LTIA) using a latex bead-immobilized anti-adiponectin polyclonal antibody. The assay was performed on a Hitachi H7170 analyzer and evaluated for validity as a method to quantitate adiponectin, in parallel with the ELISA. Results: Dilution tests using LTIA showed linearity from 0.25 to 30 mug/ml. Within-run CV and total CV were obtained
in the range of 0.8-1.9% and 1.1-2.0%, respectively. No interference was
observed in the testing of specimens containing potentially interfering
substances such as bilirubin, ditaurobilirubin, hemoglobin triglyceride,
rheumatoid factor, type IV collagen, fibronectin, and complement factor
(C1q). A strong correlation between LTIA and ELISA was confirmed (n = 30, r
= 0.990, y = 0.95x + 0.39). Conclusion: The LTIA assay is applicable to quantitating the serum concentration of adiponectin. This assay is more convenient and faster than ELISA and suitable for clinical routine analysis.

16/7/6 (Item 1 from file: 72)
DIALOG(R)File 72:EMBASE

0081458323 EMBASE No: 2006521414
Serum adiponectin levels and enzyme markers of liver dysfunction in diabetic and non-diabetic Caribbean subjects
Ezenwaka C.E.; Kalloo R.; Uhlig M.; Schwenk R.; Eckel J.
Unit of Pathology and Microbiology, Faculty of Medical Sciences, University of the West Indies, St. Augustine, Trinidad and Tobago
AUTHOR EMAIL: cezenwaka@fms.uwi.tt
CORRESP. AUTHOR/AFFIL: Ezenwaka C.E.: Unit of Pathology and Microbiology,
Faculty of Medical Sciences, University of the West Indies, St. Augustine,
Trinidad and Tobago
CORRESP. AUTHOR EMAIL: cezenwaka@fms.uwi.tt

British Journal of Biomedical Science (Br. J. Biomed. Sci.) (United

Kingdom) November 6, 2006, 63/3 (117-122)
CODEN: BJMSE ISSN: 0967-4845
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 28

Low adiponectin levels are associated with elevated plasma alanine aminotransferase, a marker of reduced hepatic insulin sensitivity and a
risk factor for type 2 diabetes. This study aims to determine the relationship between serum adiponectin level and alanine aminotransferase in diabetic and non-diabetic subjects. Fifty-six type 2
diabetic patients and 33 non-diabetic subjects participate in the study.
Baseline plasma concentrations of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and glucose are measured on a chemistry analyser. Insulin and adiponectin are measured using enzyme-linked immunoassay techniques and insulin resistance is determined using the homeostatic model assessment method. Diabetic patients
showed significantly lower levels of serum adiponectin than did the non-diabetic subjects, whereas levels of alanine aminotransferase and alkaline phosphatase were similar in both groups. While female non-diabetic
subjects showed higher serum adiponectin levels than did female diabetic patients, alanine aminotransferase level did not differ (P>0.05).
No significant relationship was seen between adiponectin and alanine aminotransferase in diabetic and non-diabetic subjects (P>0.05). Serum adiponectin levels were higher in non-diabetic subjects but there was no significant correlation between adiponectin and alanine aminotransferase in both groups of subjects. The data suggest that low serum adiponectin level may not be a suitable marker for impaired liver function in diabetic patients.

16/7/7 (Item 2 from file: 72)
DIALOG(R)File 72:EMBASE

0081228170 EMBASE No: 2006290340
Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in south-Asians
Wasim H.; Al-Daghri N.M.; Chetty R.; McTernan P.G.; Barnett A.H.; Kumar
S.
Queen Elizabeth Hospital, Birmingham University, Birmingham, United Kingdom
AUTHOR EMAIL: Wasim.Hanif@uhb.nhs.uk; aldaghri2000@hotmail.com; nma@myway.com; P.G.McTernan@warwick.ac.uk; aldaghi2000@hotmail.com; Sudhesh.Kumar@warwick.ac.uk

CORRESP. AUTHOR/AFFIL: Al-Daghri N.M.: King Saud University, College of Science, Biochemistry Department, Riyadh, Saudi Arabia
CORRESP. AUTHOR EMAIL: aldaghri2000@hotmail.com

Cardiovascular Diabetology (Cardiovasc. Diabetol.) (United Kingdom)
May 2, 2006, 5/-
CODEN: CDAIA ISSN: 1475-2840 eISSN: 1475-2840
DOI: 10.1186/1475-2840-5-10
URL: http://www.cardiab.com/content/5/1/10
ARTICLE NUMBER: 10
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 38

Objectives: South-Asians have lower adiponectin levels compared to Caucasians. It was not clear however, if this intrinsic feature is related to aspects of glucose metabolism. This study aims to determine the relationship between body fat distribution and adipocytokine in South-Asian subjects by measuring serum adipocytokines, adiposity, insulinemia, and glucose tolerance levels. Methods: In this cross-sectional study, 150 South-Asians (80 males, 70 females) were included, 60 had NGT (Control group, Age 51.33 +/- 11.5, BMI 27 +/- 2.3), 60 had IGT (Age 57.7 +/- 12.5, BMI 27.2 +/- 2.7), 30 had type 2 DM (Age 49.5 +/- 10.9, BMI 28 +/- 1.7). Measures of adiposity, adipocytokines and other metabolic parameters were determined. Parameters were measured using the following: a) Plasma glucose by glucose oxidase method b) CRP by immunoturbidimetric method (Roche/Hitachi analyser) c) insulin by Medgenix INS-ELISA immunoenzymetric assay by Biosource (Belgium) d) Leptin, Adiponectin by radioimmunoassay kits by Linco Research (St. Charles MO) e) Resistin by immunoassay kits by Phoenix Pharmaceuticals INC (530 Harbor Boulevard, Belmont CA 94002, USA). Results: Adiponectin concentrations were highest in NGT, decreased in IGT and lowest in DMT2, (both $p < 0.01$). Leptin was significantly higher in DMT2 than IGT and NGT $p = 0.02$ and 0.04 respectively. There was a significant positive relationships between log adiponectin and 2-hr insulin values, $p = 0.028$ and history of hypertensions and a ischemic heart disease $p = 0.008$ with $R = 0.65$. There was a significant inverse correlation between log adiponectin and resistin, $p < 0.01$. Conclusion: Resistin levels had

an inverse correlation with adiponectin levels, indicating an inverse relationship between pro-inflammatory cytokines and adiponectin. Adiponectin levels were related to glucose tolerance. (c) 2006 Wasim et al; licensee BioMed Central Ltd.

16/7/8 (Item 1 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

17249907 PMID: 16759463
[Study on the relationship between serum adiponectin and insulin resistance in women with polycystic ovary syndrome]
Yang Xue-feng; Ren Fen-ruo; Guo Shu-ping
Department of Obstetrics and Gynecology, Third Affiliated Hospital,
Zhengzhou University, Zhengzhou 450052, China.
Zhonghua fu chan ke za zhi (China) Apr 2006, 41 (4) p261-3, ISSN
0529-567X--Print Journal Code: 16210370R
Publishing Model Print
Document type: English Abstract; Journal Article; Research Support,
Non-U.S. Gov't
Languages: CHINESE
Main Citation Owner: NLM
Record type: MEDLINE; Completed
OBJECTIVE: To study the relationship between serum adiponectin and insulin resistance in women with polycystic ovary syndrome (PCOS). METHODS:
Forty women with PCOS and twenty five healthy women were divided into PCOS
obese group [body weight index (BMI) > or = 25kg/m(2)], PCOS non-obese
group (BMI < 25 kg/m(2)) and control group. There are 19 cases in PCOS
obese group and 21 cases in PCOS non-obese group, 9 cases in obese control
group and 16 in non-obese control group. Serum adiponectin levels of the four groups were detected by enzyme linked immunosorbent assay (ELISA) method, insulin by electrochemiluminescence immunoassay method, blood sugar by glucose oxidation enzyme method, tumor necrosis
factor-alpha (TNF-alpha) by radioimmunoassay. Insulin sensitivity index
(ISI) was calculated. RESULTS: (1) Serum adiponectin levels of PCOS obese group was (1.6 +/- 0.5) mg/L, of PCOS non-obese group was (3.0 +/-
0.6) mg/L. Their values were lower than obese control group (3.2 +/- 0.3)
mg/L, and non-obese control group (4.9 +/- 0.5) mg/L (P < 0.05). (2)

Fasting insulin levels of PCOS obese group was (17 +/- 6) mU/L, PCOS non-obese group was (14 +/- 6) mU/L. They were higher than obese control group (10 +/- 3) mU/L, and non-obese control group (7 +/- 3) mU/L (P < 0.05). (3) Fasting blood sugar level was (5.2 +/- 0.7) mmol/L in PCOS obese group, in PCOS non-obese group was (5.1 +/- 0.6) mmol/L, in obese control group was (5.4 +/- 0.5) mmol/L, and non-obese control group (4.8 +/- 0.6) mmol/L, without marked difference among four groups. (4) TNF-alpha levels of PCOS obese group was (1.32 +/- 0.14) microg/L, of PCOS non-obese group was (1.02 +/- 0.12) microg/L. They were higher than obese control group (0.93 +/- 0.15) microg/L, and non-obese control group (0.63 +/- 0.18) microg/L (P < 0.05). (5) ISI of PCOS obese group was -4.5 +/- 0.3, PCOS non-obese group was -4.1 +/- 0.4. Their values were lower than obese control group -3.6 +/- 0.3, and non-obese control group (-3.1 +/- 0.4) (P < 0.05). Serum adiponectin levels of the women with PCOS were correlated negatively with BMI (r = -0.56, P < 0.05), and correlated positively with ISI (r = 0.49, P < 0.05). CONCLUSION: Serum adiponectin levels of women with PCOS is decreased compared with healthy women, particularly in obese women with PCOS. The decrease is correlated with ISI.

Record Date Created: 20060608
Record Date Completed: 20080214

16/7/9 (Item 2 from file: 154)
DIALOG(R)File 154:MEDLINE(R)

17031789 PMID: 16427606

Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes.

Chen Baoying; Lam Karen S L; Wang Yu; Wu Donghai; Lam Michael C; Shen Jiangang; Wong Laiching; Hoo Ruby L C; Zhang Jialiang; Xu Aimin
Department of Medicine, University of Hong Kong, Hong Kong, China.

Biochemical and biophysical research communications (United States) Mar

10 2006, 341 (2) p549-56, ISSN 0006-291X--Print Journal Code: 0372516
Publishing Model Print-Electronic
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
Low plasma levels of adiponectin (hypoadiponectinemia) and elevated circulating concentrations of plasminogen activator inhibitor (PAI)-1 are causally associated with obesity-related insulin resistance and cardiovascular disease. However, the mechanism that mediates the aberrant production of these two adipokines in obesity remains poorly understood. In this study, we investigated the effects of hypoxia and reactive oxygen species (ROS) on production of adiponectin and PAI-1 in 3T3-L1 adipocytes. Quantitative PCR and immunoassays showed that ambient hypoxia markedly suppressed adiponectin mRNA expression and its protein secretion, and increased PAI-1 production in mature adipocytes. Dimethyloxallyl glycine, a stabilizer of hypoxia-inducible factor 1alpha (HIF-1alpha), mimicked the hypoxia-mediated modulations of these two adipokines. Hypoxia caused a modest elevation of ROS in adipocytes. However, ablation of intracellular ROS by antioxidants failed to alleviate hypoxia-induced aberrant production of adiponectin and PAI-1. On the other hand, the antioxidants could reverse hydrogen peroxide (H2O2)-induced dysregulation of adiponectin and PAI-1 production. H2O2 treatment decreased the expression levels of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein (C/EBPalpha), but had no effect on HIF-1alpha, whereas hypoxia stabilized HIF-1alpha and decreased expression of C/EBPalpha, but not PPARgamma. Taken together, these data suggest that hypoxia and ROS decrease adiponectin production and augment PAI-1 expression in adipocytes via distinct signaling pathways. These effects may contribute to hypoadiponectinemia and elevated PAI-1 levels in obesity, type 2 diabetes, and cardiovascular diseases.

Record Date Created: 20060131
Record Date Completed: 20060418
Date of Electronic Publication: 20060113

16/7/10 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

147498180 CA: 147(24)498180j JOURNAL
Quickly detecting the content of plasma Acrp30 by competitive ELISA
AUTHOR(S): Hu, Xiaobo; Yan, Zhiqiang; Chen, Xia; Yang, Shengli; Xu, Jinhua; Gong, Yi
LOCATION: Shanghai Institutes for Biological Sciences, Chinese Academy of Science, Shanghai, Peop. Rep. China, 200233
JOURNAL: Nanhua Daxue Xuebao, Yixueban (Nanhua Daxue Xuebao, Yixueban)
DATE: 2006 VOLUME: 34 NUMBER: 1 PAGES: 37-39,43 CODEN: NDXYAD ISSN: 1672-7444 LANGUAGE: Chinese PUBLISHER: Nanhua Daxue Jikanshe
SECTION:
CA209010 Biochemical Methods
CA213XXX Mammalian Biochemistry
IDENTIFIERS: adiponectin globular head domain immunogen competitive ELISA
blood antigen
DESCRIPTORS:
Protein motifs...
C-terminal globular head domain of Acrp30; quickly detecting the content of plasma Acrp30 by competitive ELISA
Enzyme-linked immunosorbent assay...
competitive; quickly detecting the content of plasma Acrp30 by competitive ELISA
Adiponectins... Antigens... Antiserums... Blood plasma... Immunoassay...
Oryctolagus cuniculus... Rabbit...
quickly detecting the content of plasma Acrp30 by competitive ELISA
Proteins...
recombinant, Acrp30; quickly detecting the content of plasma Acrp30 by
competitive ELISA
CAS REGISTRY NUMBERS:
7664-93-9 uses, quickly detecting the content of plasma Acrp30 by competitive ELISA

16/7/11 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

145389427 CA: 145(20)389427h PATENT
Inhibition of wet type age related macular degeneration (amd) by adiponectin or acrp 30
INVENTOR(AUTHOR): Bora, Puran S.; Bora, Nalini S.; Kaplan, Henry J.
LOCATION: USA
ASSIGNEE: University of Louisville Research Foundation, Inc.
PATENT: PCT International ; WO 2006104964 A2 DATE: 20061005
APPLICATION: WO 2006US11008 (20060322) *US 2005PV665702 (20050328)
PAGES: 34pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0038/17 A I F B 20060101 H US
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK;
LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ;
OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR;
TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
SECTION:
CA201012 Pharmacology
CA202XXX Mammalian Hormones
IDENTIFIERS: wet age macular degeneration adiponectin, peptide choroidal
neovascularization inhibitor
DESCRIPTORS:
Cytokines...
adiponectin, expression in laser-induced mouse model of wet type age
related macular degeneration; inhibition of wet type age related
macular degeneration by adiponectin
Cytokines...
adiponectin, functional fragment; inhibition of wet type age related
macular degeneration by adiponectin
Cytokines...
adiponectin; inhibition of wet type age related macular degeneration by
adiponectin
Eye...

degeneration by adiponectin
Eye...
pigment epithelium; inhibition of wet type age related macular
degeneration by adiponectin
Eye,disease...
retina, neovascularization; inhibition of wet type age related
macular
degeneration by adiponectin
Epithelium...
retinal pigment; inhibition of wet type age related macular
degeneration by adiponectin
PCR(polymerase chain reaction)...
RT-PCR (reverse transcription-PCR); inhibition of wet type age
related
macular degeneration by adiponectin
CAS REGISTRY NUMBERS:
127464-60-2 106096-92-8 expression in laser-induced mouse model of
wet
type age related macular degeneration; inhibition of wet type age
related macular degeneration by adiponectin
911196-25-3 911196-26-4 911196-27-5 inhibition of wet type age
related
macular degeneration by adiponectin
911526-58-4 911526-59-5 911526-60-8 911526-61-9 911526-62-0
911526-63-1 unclaimed nucleotide sequence; inhibition of wet
type age
related macular degeneration (amd) by adiponectin or acrp 30
911196-25-3D 911196-26-4D 911196-27-5D variant, inhibition of wet
type
age related macular degeneration by adiponectin

16/7/12 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

145331020 CA: 145(17)331020d JOURNAL
Fundamental study of adiponectin of the high molecular weight for a
checkup by mail
AUTHOR(S): Miyake, Chieko; Shioya, Harumi; Kasugai, Tatsuzou
LOCATION: Aichi Medical Foundation of Diagnostic Technology, 4-23-2
Chiyoda, Naka-ku, Nagoya-shi, Aichi, Japan, 460-0012
JOURNAL: Iryo to Kensa Kiki-Shiyaku (Iryo to Kensa Kiki-Shiyaku)
DATE:
2005 VOLUME: 28 NUMBER: 6 PAGES: 535-543 CODEN: IKKRAN ISSN:
1347-0434
LANGUAGE: Japanese PUBLISHER: Rinsho Byori Kankokai
SECTION:
CA209010 Biochemical Methods
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: adiponectin plasma ELISA dry blood paper metabolic
syndrome

DESCRIPTORS:
Cytokines...
adiponectin; ELISA fundamental study of adiponectin of high mol. wt.
for checkup by mail
Blood analysis...
ELISA fundamental study of adiponectin of high mol. wt. for checkup by
mail
Immunoassay...
enzyme-linked immunosorbent assay; ELISA fundamental study of
adiponectin of high mol. wt. for checkup by mail
Metabolic disorders...
metabolic syndrome X; ELISA fundamental study of adiponectin of high
mol. wt. for checkup by mail

16/7/13 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

145058842 CA: 145(4)58842e PATENT
Multiplexed assay methods for analytes of different abundances using immunoassays combined with electrochemiluminescence
INVENTOR(AUTHOR): Stromgren, Selen A.; Glezer, Eli N.
LOCATION: USA
ASSIGNEE: Meso Scale Technologies, Llc.
PATENT: U.S. Pat. Appl. Publ. ; US 20060134712 A1 DATE: 20060622
APPLICATION: US 2005249077 (20051012) *US 2004PV618713 (20041014)
PAGES: 13 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007920
IPCR/8 + Level Value Position Status Version Action Source Office:
G01N-0033/537 A I F B 20060101 20060622 H US
G01N-0033/53 A I L B 20060101 20060622 H US
G01N-0033/543 A I L B 20060101 20060622 H US
SECTION:
CA209010 Biochemical Methods
IDENTIFIERS: immunofluorescence assay analyte concn
DESCRIPTORS:
Cytokines...
adiponectin; multiplexed assay methods for analytes of different abundances using immunoassays combined with electrochemiluminescence
Chemiluminescence...
electrochemiluminescence; multiplexed assay methods for analytes of different abundances using immunoassays combined with electrochemiluminescence
Immunoassay...
enzyme-linked immunosorbent assay; multiplexed assay methods for

analytes of different abundances using immunoassays combined with electrochemiluminescence
Glass,uses... Fluorescence immunoassay... Magnetic particles... Dilution...
Concentration(condition)...
multiplexed assay methods for analytes of different abundances using
immunoassays combined with electrochemiluminescence
CAS REGISTRY NUMBERS:
9004-10-8 analysis, multiplexed assay methods for analytes of different
abundances using immunoassays combined with electrochemiluminescence
482618-42-8 169494-85-3 multiplexed assay methods for analytes of
different abundances using immunoassays combined with electrochemiluminescence

16/7/14 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

144428491 CA: 144(23)428491a PATENT
Methods and compositions for diagnosis, stratification, and monitoring of
Alzheimer's disease and other neurological disorders in body fluids
INVENTOR(AUTHOR): Ray, Sandip; Wyss-Coray, Anton
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20060094064 A1 DATE: 20060504
APPLICATION: US 2005148595 (20050608) *US 2003PV523796 (20031119) *US
2004PV566783 (20040430) *US 2004PV566782 (20040430) *US 2004993813 (20041119)
PAGES: 52 pp., Cont.-in-part of U.S. Ser. No. 993,813. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007200
IPCR/8 + Level Value Position Status Version Action Source Office:
G01N-0033/53 A I F B 20060101 20060504 H US
G01N-0033/567 A I L B 20060101 20060504 H US
SECTION:
CA209010 Biochemical Methods
CA202XXX Mammalian Hormones
CA214XXX Mammalian Pathological Biochemistry
CA215XXX Immunochemistry
IDENTIFIERS: immunoassay biomarker Alzheimer disease diagnosis
DESCRIPTORS:
Cytokines...
adiponectin; methods and immunoassays for diagnosis, stratification and
monitoring of Alzheimer's disease and other neurol. disorders in body

other neurol. disorders in body fluids
Interferons...
γ; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in body fluids
Cell adhesion molecules...
ICAM-1 (intercellular adhesion mol. 1); methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in body fluids
Insulin-like growth factor-binding proteins...
IGFBP-1; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in body fluids
Insulin-like growth factor-binding proteins...
IGFBP-2; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in body fluids
Insulin-like growth factor-binding proteins...
IGFBP-4; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in body fluids
Chemokines...
lymphotactin; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in body fluids
Proteins...
macrophage-stimulating, α-chain; methods and immunoassays for diagnosis, stratification and monitoring of Alzheimer's disease and other neurol. disorders in body fluids
Macrophage inflammatory protein 4... Hepatocyte growth factor... Lymphotoxin... Interleukin 6 receptors... Ciliary neurotrophic factor...
Interleukin 8... Interleukin 11... Test kits... Antibodies and Immunoglobulins... Blood analysis... Human... Biomarkers... Alzheimer's
disease... Bone morphogenetic protein 6... Bone morphogenetic protein 4...
Eotaxin 2... RANTES(chemokine)... Urokinase-type plasminogen activator receptors... Neutrophil-activating peptide-2... Interleukin 1 receptor antagonist... Interleukin 3... Monocyte chemoattractant protein-1...

Macrophage inflammatory protein 1β... Fas antigen... Epidermal growth factor receptors... Monocyte chemoattractant protein-2... Immunoassay...
methods and immunoassays for diagnosis, stratification and monitoring
of Alzheimer's disease and other neurol. disorders in body fluids
Chemokines...
SDF-1 (stromal-derived factor-1); methods and immunoassays for
diagnosis, stratification and monitoring of Alzheimer's disease and
other neurol. disorders in body fluids
Proteins...
SR; methods and immunoassays for diagnosis, stratification and
monitoring of Alzheimer's disease and other neurol. disorders in body
fluids
Cytokine receptors...
TRAIL-R3; methods and immunoassays for diagnosis, stratification and
monitoring of Alzheimer's disease and other neurol. disorders in body
fluids
Tumor necrosis factor receptors...
type 2, sol.; methods and immunoassays for diagnosis, stratification
and monitoring of Alzheimer's disease and other neurol. disorders in
body fluids
Macrophage inflammatory proteins...
1δ; methods and immunoassays for diagnosis, stratification and
monitoring of Alzheimer's disease and other neurol. disorders in body
fluids
CAS REGISTRY NUMBERS:
143011-72-7 250740-90-0 140208-24-8 124861-55-8 169494-85-3
62229-50-9
130939-66-1 130939-41-2 106096-93-9 123584-45-2 192662-83-2
67763-96-6 194368-66-6 410093-94-6 9014-42-0 83869-56-1
methods
and immunoassays for diagnosis, stratification and monitoring of
Alzheimer's disease and other neurol. disorders in body fluids

16/7/15 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

144382055 CA: 144(21)382055f JOURNAL
Human adiponectin ELISA kit for total and multimers
AUTHOR(S): Abe, Satoko
LOCATION: Daiichi Pure Chemicals, Japan,
JOURNAL: BIO Clin. (BIO Clinica) DATE: 2006 VOLUME: 21 NUMBER: 1

PAGES: 59-62 CODEN: BCILCY ISSN: 0919-8237 LANGUAGE: Japanese
PUBLISHER: Hokuryukan
SECTION:
CA202000 Mammalian Hormones
IDENTIFIERS: review blood adiponectin detn ELISA
DESCRIPTORS:
Cytokines...
adiponectin; ELISA kit for detn. of blood total and multimers of human
adiponectin
Blood analysis... Human...
ELISA kit for detn. of blood total and multimers of human adiponectin
Immunoassay...
enzyme-linked immunosorbent assay; ELISA kit for detn. of blood total
and multimers of human adiponectin

16/7/16 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

143114066 CA: 143(7)114066c PATENT
Systems and methods for characterizing kidney diseases
INVENTOR(AUTHOR): Hu, Huaizhong; Knechtle, Stuart; Aizenstein, Brian D.
LOCATION: USA
ASSIGNEE: Renovar Incorporated
PATENT: U.S. Pat. Appl. Publ. ; US 20050158801 A1 DATE: 20050721
APPLICATION: US 200410685 (20041213) *US 2002313807 (20021206) *US 2004903797 (20040730)
PAGES: 31 pp., Cont.-in-part of U.S. Ser. No. 9037,97. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007200; G01N-033/53A; G01N-033/567B; G01N-033/537B; G01N-033/543B
SECTION:
CA215008 Immunochemistry
CA209XXX Biochemical Methods
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: system characterizing kidney disease
DESCRIPTORS:
Cytokines...
adiponectin; systems and methods for characterizing kidney diseases
Diagnosis...
agents; systems and methods for characterizing kidney diseases
Transplant and Transplantation... Transplant rejection...
allotransplant; systems and methods for characterizing kidney diseases

Immunoassay...
    enzyme-linked immunosorbent assay; systems and methods for characterizing kidney diseases
Cytometry...
    flow; systems and methods for characterizing kidney diseases
Kidney,disease... Inflammation...
    glomerulonephritis; systems and methods for characterizing kidney diseases
Insulin-like growth factor-binding proteins...
    IGFBP-1; systems and methods for characterizing kidney diseases
Insulin-like growth factor-binding proteins...
    IGFBP-2; systems and methods for characterizing kidney diseases
Insulin-like growth factor-binding proteins...
    IGFBP-6; systems and methods for characterizing kidney diseases
Immunoassay...
    immunopptn.; systems and methods for characterizing kidney diseases
Chemokines...
    interferon γ-inducible protein-10; systems and methods for characterizing kidney diseases
Transplant and Transplantation...
    kidney, rejection, urine IP-10 chemokine in relation to; systems and
    methods for characterizing kidney diseases
Chemokines...
    Mig (monokine induced by interferon-γ); systems and methods for characterizing kidney diseases
BK virus...
    nephritis from infection with; systems and methods for characterizing
    kidney diseases
Proteins...
    Osteoprotogerin; systems and methods for characterizing kidney diseases
Immunoassay...
    radioimmunoassay; systems and methods for characterizing kidney diseases
Injury... Injury...
    renal tubular; systems and methods for characterizing kidney diseases
Tumor necrosis factors...
    sR1; systems and methods for characterizing kidney diseases
Interleukin 8... Monocyte chemoattractant protein-1...
Kidney,disease...
Test kits... Urine analysis... Statistical analysis... Microarray technology... Microspheres... Blood serum... Blood analysis... Macrophage
inflammatory protein 1α... Macrophage inflammatory protein 1β...
Antibodies and Immunoglobulins... Macrophage inflammatory protein 3α ...
    systems and methods for characterizing kidney diseases
Kidney...

transplant, rejection, urine IP-10 chemokine in relation to; systems
and methods for characterizing kidney diseases
Kidney,disease... Kidney,disease...
tubular injury; systems and methods for characterizing kidney diseases
Kidney,disease...
tubulointerstitial; systems and methods for characterizing kidney diseases
Proteins...
uPAR; systems and methods for characterizing kidney diseases
CAS REGISTRY NUMBERS:
169494-85-3 60-27-5 systems and methods for characterizing kidney diseases

16/7/17 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

143022448 CA: 143(2)22448a JOURNAL
Assay performance of "human adiponectin ELISA kit" and evaluation of high
molecular weight form of adiponectin
AUTHOR(S): Akamatsu, Suguru; Sakamoto, Yuichi
LOCATION: Department of New Products Development, Otsuka Life Science
Initiative, Otsuka Pharmaceutical Co., Ltd., Japan,
JOURNAL: BIO Clin. (BIO Clinica) DATE: 2004 VOLUME: 19 NUMBER: 13
PAGES: 1094-1099 CODEN: BCILCY ISSN: 0919-8237 LANGUAGE: Japanese
PUBLISHER: Hokuryukan
SECTION:
CA209010 Biochemical Methods
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: human adiponectin ELISA kit assay assessment
DESCRIPTORS:
Adipose tissue...
adipocyte, white; assay performance of human adiponectin ELISA kit and
evaluation of high mol. wt. form of adiponectin
Cytokines...
adiponectin; assay performance of human adiponectin ELISA kit and
evaluation of high mol. wt. form of adiponectin
Human... Test kits... Diagnosis...
assay performance of human adiponectin ELISA kit and evaluation of high
mol. wt. form of adiponectin
Immunoassay...
enzyme-linked immunosorbent assay; assay performance of human
adiponectin ELISA kit and evaluation of high mol. wt. form of
adiponectin
Molecular weight...

heterogeneities by difference in; assay performance of human adiponectin ELISA kit and evaluation of high mol. wt. form of adiponectin

16/7/18 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

142407211 CA: 142(22)407211c PATENT
Method of separating and assaying adiponectin multimer
INVENTOR(AUTHOR): Ebinuma, Hiroyuki; Yago, Hirokazu; Akimoto, Yuka; Miyazaki, Osamu; Kadowaki, Takashi; Yamauchi, Toshimasa; Hara, Kazuo
LOCATION: Japan,
ASSIGNEE: Daiichi Pure Chemicals Co., Ltd.; Toudai Tlo, Ltd.
PATENT: PCT International ; WO 200538457 A1 DATE: 20050428
APPLICATION: WO 2004JP15260 (20041015) *JP 2003354930 (20031015)
PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: Japanese
PATENT CLASSIFICATIONS:
CLASS: G01N-033/53A; G01N-027/447B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG
SECTION:
CA209016 Biochemical Methods
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: adiponectin ELISA proteinase sepg multimer human blood disease diagnosis
DESCRIPTORS:
Cytokines...
adiponectin, including various multimers from human blood; method of
sepg. and assaying adiponectin multimer
Immunoassay...
enzyme-linked immunosorbent assay; method of sepg. and assaying adiponectin multimer

Disease,animal...
    metabolic syndrome X; method of sepg. and assaying adiponectin multimer
Disulfide group... Immunoassay... Human... Blood...
Albumins,reactions...
Kidney,disease... Liver,disease... Arteriosclerosis... Obesity... Gel permeation chromatography... Gel electrophoresis...
Digestion,chemical...
Sample preparation...
    method of sepg. and assaying adiponectin multimer
Diabetes mellitus...
    non-insulin-dependent; method of sepg. and assaying adiponectin multimer
Antibodies and Immunoglobulins...
    to albumin, to adiponectin; method of sepg. and assaying adiponectin multimer
  CAS REGISTRY NUMBERS:
9001-92-7 9003-05-8 9014-01-1 66676-43-5 209864-06-2 305344-27-8
    method of sepg. and assaying adiponectin multimer

 16/7/19   (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

  142407182   CA: 142(22)407182u   PATENT
  Method of pretreating sample and immunological assay method using the
  same
  INVENTOR(AUTHOR): Ebinuma, Hiroyuki; Yago, Hirokazu; Akimoto, Yuka; Miyazaki, Osamu; Kadowaki, Takashi; Yamauchi, Toshimasa
  LOCATION: Japan,
  ASSIGNEE: Daiichi Pure Chemicals Co., Ltd.; Toudai Tlo, Ltd.
  PATENT: PCT International ; WO 200538458 A1 DATE: 20050428
  APPLICATION: WO 2004JP15261 (20041015) *JP 2003354715 (20031015)
  PAGES: 30 pp. CODEN: PIXXD2 LANGUAGE: Japanese
  PATENT CLASSIFICATIONS:
    CLASS: G01N-033/53A
  DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;

BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG
  SECTION:
    CA209010 Biochemical Methods
  IDENTIFIERS: adiponectin sample pretreatment immunoassay reductant
    surfactant protease human blood
  DESCRIPTORS:
Cytokines...
    adiponectin, including various multimers; method of pretreating sample
    and immunol. assay method using the same
Mixtures...
    adiponectin multimers; method of pretreating sample and immunol. assay
    method using the same
Immunoassay...
    immunoblotting; method of pretreating sample and immunol. assay method
    using the same
Immunoassay... Sample preparation... Reducing agents... Acids,uses...
Surfactants... Salts,uses... Bacillus(bacterium genus)...
Streptomyces...
Aspergillus... Human... Blood...
    method of pretreating sample and immunol. assay method using the same
Antibodies and Immunoglobulins...
    to adiponectin (mouse, human); method of pretreating sample and
    immunol. assay method using the same
  CAS REGISTRY NUMBERS:
305344-27-8 9001-92-7 3483-12-3 1185-53-1 7646-69-7 172520-74-0
    9074-07-1 25155-30-0 769136-50-7 112-03-8 9002-93-1 9005-64-5
    method of pretreating sample and immunol. assay method using the same
64-19-7 151-21-3 uses, method of pretreating sample and immunol. assay
    method using the same

 16/7/20   (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

  141223116   CA: 141(14)223116y   JOURNAL
  Canine adiponectin: Measurement of its blood concentration by ELISA and
  effects of obesity
  AUTHOR(S): Omachi, Asako; Ishioka, Katsumi; Shibata, Haruki; Honjoh,
Tsutomu; Kimura, Kazuhiro; Saito, Masayuki
  LOCATION: Lab. Biochem., Dep. Biomed. Sci., Grad. Sch. Veterinary Med.,

Hokkaido Univ., Sapporo, Japan, 060-0818
JOURNAL: Jui Seikagaku (Jui Seikagaku) DATE: 2004 VOLUME: 41 NUMBER: 1
PAGES: 31-37 CODEN: JSUEBY ISSN: 1345-921X LANGUAGE: Japanese
PUBLISHER: Jui Seikagakkai
SECTION:
CA214008 Mammalian Pathological Biochemistry
IDENTIFIERS: blood adiponectin detn ELISA obesity dog
DESCRIPTORS:
Cytokines...
adiponectin; ELISA detn. of serum adiponectin and its effects on canine
obesity
Blood serum... Obesity... Canis familiaris... Blood analysis...
ELISA detn. of serum adiponectin and its effects on canine obesity
Immunoassay...
enzyme-linked immunosorbent assay; ELISA detn. of serum adiponectin and
its effects on canine obesity
CAS REGISTRY NUMBERS:
169494-85-3 ELISA detn. of serum adiponectin and its effects on canine
obesity in relation to

16/7/21 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

141035612 CA: 141(3)35612h JOURNAL
Clinical significance of measuring adiponectin and development of quantitation method
AUTHOR(S): Tanaka, Sachiyo; Kihara, Shinji; Funahashi, Toru
LOCATION: Graduate School of Medicine, Osaka University, Japan,
JOURNAL: Kensa to Gijutsu (Kensa to Gijutsu) DATE: 2003 VOLUME: 31
NUMBER: 8 PAGES: 763-766 CODEN: KTGIDU ISSN: 0301-2611 LANGUAGE: Japanese PUBLISHER: Igaku Shoin Ltd.
SECTION:
CA209000 Biochemical Methods
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: review clin significance measurement adiponectin blood level
, ELISA quantitation adiponectin blood level review
DESCRIPTORS:
Cytokines...
adiponectin; clin. significance of measuring adiponectin and development of quantitation method
Blood analysis... Diabetes mellitus... Human... Kidney,disease... Obesity
...
clin. significance of measuring adiponectin and development of quantitation method

Immunoassay...
    enzyme-linked immunosorbent assay; clin. significance of measuring adiponectin and development of quantitation method

16/7/22 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

140371257 CA: 140(23)371257q JOURNAL
Development of an ELISA kit for mouse and rat adiponectin
AUTHOR(S): Saitoh, Toshikazu; Akamatsu, Suguru; Tachikawa, Tetsuya; Muraguchi, Masahiro; Iwata, Fusako; Ohmoto, Yasukazu
LOCATION: Department of In Vitro Diagnostics, Otsuka Life Science Initiative, Otsuka Pharmaceutical Co., Ltd., Japan,
JOURNAL: Saibo (Saibo) DATE: 2003 VOLUME: 35 NUMBER: 7 PAGES: 274-277
CODEN: SAIBC7 ISSN: 1346-7557 LANGUAGE: Japanese PUBLISHER: Nyu Saiensusha
SECTION:
CA209010 Biochemical Methods
IDENTIFIERS: ELISA kit mouse rat adiponectin
DESCRIPTORS:
Cytokines...
    adiponectin; development of ELISA kit for mouse and rat adiponectin
Test kits... Mus... Rat... Blood analysis...
    development of ELISA kit for mouse and rat adiponectin
Immunoassay...
    enzyme-linked immunosorbent assay; development of ELISA kit for mouse
    and rat adiponectin
Antibodies and Immunoglobulins...
    specific for mouse adiponectin, from rabbit serum; development of ELISA
    kit for mouse and rat adiponectin
Animal cell line...
    3T3-L1, culture supernatant of; development of ELISA kit for mouse and
    rat adiponectin

16/7/23 (Item 14 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

140252318 CA: 140(16)252318a PATENT
Monoclonal antibody against adiponectin
INVENTOR(AUTHOR): Youn, Byung-soo; Yang, Young-soo; Lee, Nam-seok; Yu, Kang-yeol; Youn, Moon-yeon; Park, Hong-je; Min, Sung-shik; Jeoung, Jae-jun

LOCATION: S. Korea
ASSIGNEE: Komed Co., Ltd.
PATENT: PCT International ; WO 200422596 A1 DATE: 20040318
APPLICATION: WO 2003KR1213 (20030619) *KR 53427 (20020905) *KR 38880 (20030616)
PAGES: 55 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-016/18A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KZ; LC; LK; LR; LS; LT; LU; LV;
MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD;
SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS
; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE;
ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ;
CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA215003 Immunochemistry
CA202XXX Mammalian Hormones
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: monoclonal antibody adiponectin
DESCRIPTORS:
Cytokines...
adiponectin; prepn. of monoclonal antibodies to
Diagnosis...
agents; monoclonal antibodies to human adiponectin for
Hybridoma...
B-cell, KCTC 10289BP; for antibodies to adiponectin
Diagnosis...
diabetes mellitus; monoclonal antibodies to human adiponectin for
Immunoassay...
enzyme-linked immunosorbent assay; monoclonal antibodies for detection
of human adiponectin
Test kits...
for immunoassay of adiponectin
Antibodies and Immunoglobulins...
IgG1, monoclonal; to human adiponectin
Antibodies and Immunoglobulins...
immunoadhesins; of human adiponectin for prepn. of monoclonal antibodies
Blood analysis...
monoclonal antibodies for detection of human adiponectin

Obesity...
    monoclonal antibodies for detection of human adiponectin in
Human... Mus... Rat... Bos taurus... Equus caballus... Rabbit...
Capra...
Mammalia...
    monoclonal antibodies to adiponectin of
Diabetes mellitus...
    non-insulin-dependent; monoclonal antibodies for detection of
human
    adiponectin in
Fusion proteins(chimeric proteins)...
    of human adiponectin for prepn. of monoclonal antibodies
Diagnosis...
    serodiagnosis; monoclonal antibodies to human adiponectin for
  CAS REGISTRY NUMBERS:
670342-21-9 670342-22-0 unclaimed nucleotide sequence; monoclonal
    antibody against adiponectin
670222-47-6 670222-48-7 670222-49-8 670222-50-1 670342-23-1
    670342-25-3 unclaimed sequence; monoclonal antibody against
    adiponectin

 16/7/24   (Item 15 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

  140140700   CA: 140(10)140700n   PATENT
  Novel polypeptides and polynucleotides obtained from human cDNA
  libraries.
  INVENTOR(AUTHOR): Rupp, Fabio; Wang, Jian-Rui; Zhou, Ping; Wehrman,
Tom;
Wang, Zhi Wei; Tang, Y. Tom
  LOCATION: USA
  ASSIGNEE: Nuvelo, Inc.
  PATENT: PCT International ; WO 200407672 A2 DATE: 20040122
  APPLICATION: WO 2003US21703 (20030709) *US PV395402 (20020712)
  PAGES: 205 pp. CODEN: PIXXD2 LANGUAGE: English
  PATENT CLASSIFICATIONS:
    CLASS: C12N-000/A
  DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD;
GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT;
RO; RU;
SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ;
VC; VN;
YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH;
GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE;
DK;

EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK;
TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
  SECTION:
    CA203003 Biochemical Genetics
    CA206XXX General Biochemistry
    CA209XXX Biochemical Methods
    CA213XXX Mammalian Biochemistry
    CA263XXX Pharmaceuticals
  IDENTIFIERS: protein cDNA sequence human
  DESCRIPTORS:
Cytokines...
    adiponectin, sequence homologs; novel polypeptides and
polynucleotides
    obtained from human cDNA libraries.
Nucleic acid hybridization... Nucleic acid amplification(method)...
Reverse
transcription...
    assay; novel polypeptides and polynucleotides obtained from human
cDNA
    libraries.
Genetic mapping...
    chromosomal; novel polypeptides and polynucleotides obtained from
human
    cDNA libraries.
Animal tissue...
    expression distribution in; novel polypeptides and polynucleotides
    obtained from human cDNA libraries.
Animal cell line...
    insect High Five, recombinant expression in; novel polypeptides
and
    polynucleotides obtained from human cDNA libraries.
Antigens...
    Ly-6, sequence homologs; novel polypeptides and polynucleotides
    obtained from human cDNA libraries.
cDNA sequences... Protein sequences... Human... Molecular cloning...
Antibodies and Immunoglobulins... Probes(nucleic acid)...
Immunoassay...
DNA microarray technology... Protein microarray technology... Drug
screening...
    novel polypeptides and polynucleotides obtained from human cDNA
    libraries.
Escherichia coli...
    recombinant expression in; novel polypeptides and polynucleotides
    obtained from human cDNA libraries.
Carcinoembryonic antigen... Chemokines...
    sequence homologs; novel polypeptides and polynucleotides
obtained from
    human cDNA libraries.
  CAS REGISTRY NUMBERS:
649581-71-5P 649581-73-7 649581-74-8 649581-76-0P 649581-78-2
    649581-80-6P 649581-82-8 649581-84-0P 649581-86-2 649581-88-4P

649581-90-8 649581-92-0P 649581-94-2 649582-00-3P 649582-02-5
649582-03-6 649582-04-7 649582-06-9P 649582-10-5P 649555-55-5
649582-12-7 649582-16-1P 649555-57-7 649582-18-3 649582-20-7P
649582-22-9 649582-23-0 649582-26-3P 649582-28-5 649582-31-0P
532378-97-5 649582-33-2 649582-34-3 amino acid sequence; novel
polypeptides and polynucleotides obtained from human cDNA
libraries.
649581-68-0 649581-69-1 649581-70-4 649581-72-6 649581-75-9
649581-77-1 649581-79-3 649581-81-7 649581-83-9 649581-85-1
649581-87-3 649581-89-5 649581-91-9 649581-93-1 649581-95-3
649581-96-4 649581-97-5 649581-98-6 649581-99-7 649582-01-4
649582-05-8 649582-07-0 649582-08-1 649582-09-2 649582-11-6
649582-13-8 649582-14-9 649582-15-0 649582-17-2 649582-19-4
649582-21-8 649582-24-1 649582-25-2 649582-27-4 649582-29-6
649582-30-9 649582-32-1 nucleotide sequence; novel polypeptides
and
polynucleotides obtained from human cDNA libraries.
649661-18-7 649661-20-1 649661-27-8 649661-30-3 649661-32-5
649661-37-0 649661-38-1 649661-39-2 unclaimed nucleotide
sequence;
novel polypeptides and polynucleotides obtained from human cDNA
libraries.
649661-14-3 649661-15-4 649661-16-5 649661-17-6 649661-19-8
649661-21-2 649661-22-3 649661-23-4 649661-24-5 649661-25-6
649661-26-7 649555-56-6 649661-28-9 649661-29-0 649661-31-4
649661-33-6 649661-34-7 649661-35-8 649661-36-9 unclaimed
protein
sequence; novel polypeptides and polynucleotides obtained from
human
cDNA libraries.

16/7/25 (Item 16 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

139031822 CA: 139(3)31822n PATENT
Polynucleotides and their encoded polypeptides from human tissues
INVENTOR(AUTHOR): Ghosh, Malabika; Tang, Y. Tom; Wang, Jian Rui;
Wang,
Zhiwei; Zhao, Qing A.; Xu, Chongjun; Mulero, Julio J.; Boyle, Bryan J.
LOCATION: USA
ASSIGNEE: Hyseq, Inc.
PATENT: PCT International ; WO 200348326 A2 DATE: 20030612
APPLICATION: WO 2002US38526 (20021202) *US 5499 (20011203)
PAGES: 396 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD;
GE; GH;

GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU;
SD; SE;
SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM;
ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS;
MW; MZ
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES;
FI;
FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SI; SK; TR; BF; BJ; CF; CG;
CI; CM;
GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
  SECTION:
    CA203003 Biochemical Genetics
    CA206XXX General Biochemistry
    CA213XXX Mammalian Biochemistry
  IDENTIFIERS: protein cDNA sequence human
  DESCRIPTORS:
Cytokines...
    adiponectin, homologs; polynucleotides and their encoded
polypeptides
    from human tissues
Nucleic acid amplification(method)... Nucleic acid hybridization...
Reverse
transcription...
    assay; polynucleotides and their encoded polypeptides from human
    tissues
Genetic mapping...
    chromosomal; polynucleotides and their encoded polypeptides from
human
    tissues
Animal tissue...
    expression profile in; polynucleotides and their encoded
polypeptides
    from human tissues
Scavenger receptors...
    homologs; polynucleotides and their encoded polypeptides from
human
    tissues
Cell adhesion molecules...
    IgCAM, homologs; polynucleotides and their encoded polypeptides
from
    human tissues
Proteins...
    lipocalin, neutrophil gelatinase-assocd., homologs;
polynucleotides and
    their encoded polypeptides from human tissues
Cell proliferation... Nerve...
    modifying proliferation of neural cells; polynucleotides and their
    encoded polypeptides from human tissues
Proteins...

mucolipin 1, homologs; polynucleotides and their encoded polypeptides
from human tissues
Proteins...
Nogo, homologs; polynucleotides and their encoded polypeptides from
human tissues
Proteins...
peroxidasin, homologs; polynucleotides and their encoded polypeptides
from human tissues
cDNA sequences... Protein sequences... Human... Molecular cloning... Antibodies... Probes(nucleic acid)... Primers(nucleic acid)... Immunoassay
... DNA microarray technology... Protein microarray technology... Proteins
...
polynucleotides and their encoded polypeptides from human tissues
Proteins...
SAPAP (synaptic-assocd. protein 90/postsynaptic d. protein 95 kDa-assocd. protein), homologs; polynucleotides and their encoded polypeptides from human tissues

CAS REGISTRY NUMBERS:

540847-66-3 540847-68-5 540745-49-1 540745-51-5 540745-53-7
540745-55-9 540745-57-1 540745-59-3 540847-70-9 540847-72-1
540847-73-2 540847-74-3 540847-78-7 540745-64-0 540847-80-1
540847-81-2 540745-65-1 540745-66-2 540745-67-3 540745-68-4
540745-69-5 540745-70-8 540745-71-9 540745-72-0 540745-73-1
540745-74-2 540745-75-3 540745-76-4 540745-77-5 540745-78-6
540745-79-7 540745-80-0 540745-81-1 540745-82-2 540745-83-3
540745-84-4 540745-85-5 540745-86-6 540745-87-7 540745-88-8
540745-89-9 540745-90-2 540745-91-3 540745-92-4 540745-93-5
540745-94-6 540745-95-7 540745-96-8 540745-97-9 540745-98-0
540745-99-1 540746-00-7 540746-01-8 540746-02-9 540746-03-0
540746-04-1 540746-05-2 540746-06-3 540746-07-4 540746-08-5
540746-09-6 540746-11-0 540746-12-1 540746-13-2 540746-14-3
540746-15-4 540746-16-5 540746-17-6 540746-18-7 540746-19-8
540746-20-1 540746-21-2 540746-22-3 540746-23-4 540746-24-5
540746-25-6 540746-26-7 540746-27-8 540746-28-9 540746-29-0
540746-30-3 540746-31-4 540746-32-5 540746-33-6 540746-34-7
540746-35-8 540746-36-9 540746-37-0 540746-38-1 540746-39-2
540746-40-5 540746-41-6 540746-42-7 540746-43-8 540746-44-9
540746-45-0 540746-46-1 540746-47-2 540746-48-3 540746-49-4
540746-50-7 540746-51-8 540746-52-9 540746-53-0 540746-54-1
540746-55-2 540746-56-3 540746-57-4 540746-58-5 540746-59-6
540746-60-9 540847-82-3 540847-83-4 540847-84-5 540746-61-0
540746-62-1 540746-63-2 540746-64-3 540746-65-4 540746-66-5
540746-67-6 540746-68-7 540746-69-8 540746-70-1 540746-71-2
540746-72-3 540746-74-5 540746-75-6 540847-85-6 540746-76-7
540746-78-9 540746-79-0 540746-80-3 540746-81-4 540746-82-5
540746-83-6 540746-84-7 540746-85-8 540746-86-9 540847-86-7
540847-90-3 540746-87-0 540847-92-5 540847-93-6 540746-88-1

540746-89-2 540746-90-5 540746-91-6 540746-92-7 540746-93-8
540746-94-9 540746-95-0 540746-96-1 540746-97-2 540746-98-3
540746-99-4 540747-00-0 540747-01-1 540747-02-2 540747-03-3
540747-04-4 540847-94-7 540847-98-1 540747-05-5 540848-00-8
540848-01-9 540747-06-6 540747-07-7 540747-08-8 540747-09-9
540747-10-2 540747-11-3 540747-12-4 540747-13-5 540747-14-6
540747-15-7 540747-16-8 540747-17-9 540747-18-0 540747-19-1
540747-20-4 540747-21-5 540747-22-6 540747-23-7 540747-24-8
540747-25-9 540747-26-0 540747-27-1 540747-28-2 540848-03-1
540848-05-3 540747-29-3 540747-30-6 540747-31-7 540747-32-8
540747-33-9 540747-34-0 540848-07-5 540848-09-7 540747-35-1
540747-36-2 540747-37-3 540747-38-4 540848-11-1 540848-13-3
540848-14-4 540848-17-7 540848-19-9 540747-39-5 540747-40-8
540747-41-9 540747-42-0 540747-43-1 540747-44-2 540747-45-3
540747-46-4 540747-47-5 540747-48-6 540747-49-7 540747-50-0
540747-51-1 540747-52-2 540848-20-2 540747-53-3 540747-54-4
540848-22-4 540747-55-5 540848-24-6 540848-28-0 540848-30-4
540747-56-6 540848-31-5 540848-34-8 540747-57-7 540848-36-0
540848-37-1 540747-58-8 540747-59-9 540747-60-2 540747-61-3
540747-62-4 540747-63-5 540747-64-6 540747-65-7 540747-66-8
540747-67-9 540747-68-0 540747-69-1 540747-70-4 540747-71-5
540848-38-2 540747-72-6 540747-73-7 540848-40-6 540848-42-8
540747-74-8 540747-75-9 540747-76-0 540848-46-2 540848-48-4
540747-77-1 540747-78-2 540747-79-3 540747-80-6 540848-49-5
540848-52-0 540747-81-7 540747-82-8 540747-83-9 540747-84-0
540747-85-1 540747-86-2 540747-88-4 540747-89-5 540747-90-8
540747-91-9 540747-92-0 540747-93-1 540747-94-2 540747-95-3
540848-54-2 540747-96-4 540848-55-3 540848-56-4 540848-60-0
540848-61-1 354525-58-9 354525-59-0 354525-60-3 354525-61-4
540747-97-5 540747-98-6 354525-64-7 354525-65-8 354525-66-9
354525-67-0 354525-68-1 354525-69-2 354525-71-6 540747-99-7
354525-73-8 354525-74-9 540748-00-3 540748-01-4 540748-03-6
540748-04-7 540748-05-8 540748-06-9 540748-07-0 540748-08-1
540748-09-2 540748-10-5 540748-11-6 540748-12-7 540748-13-8
540748-14-9 540748-15-0 540748-16-1 540748-17-2 540748-18-3
540848-62-2 540848-63-3 540848-64-4 540748-19-4 540848-67-7
540748-20-7 540848-69-9 540848-70-2 540848-71-3 540848-72-4
540848-73-5 540848-74-6 540848-75-7 540848-76-8 540848-77-9
540848-78-0 540748-21-8 540848-79-1 540848-82-6 540748-22-9
540848-84-8 540848-85-9 540848-86-0 540748-23-0 540848-87-1
540848-90-6 540848-91-7 540848-92-8 540848-93-9 540848-94-0
540848-95-1 540848-96-2 540848-97-3 540849-00-1 540849-02-3
540849-03-4 540849-04-5 540849-05-6 540849-06-7 540849-07-8
540849-08-9 540748-24-1 540849-09-0 540849-11-4 540849-13-6
540748-25-2 540849-14-7 540849-16-9 540849-18-1 540748-26-3
540748-27-4 540849-19-2 540849-21-6 540849-23-8 540849-24-9
540748-28-5 540748-29-6 540748-30-9 540748-31-0 540748-32-1
540849-25-0 540849-26-1 540849-29-4 540748-33-2 540849-31-8
540748-34-3 540849-34-1 540849-36-3 540748-35-4 540748-36-5
540849-37-4 540849-38-5 540849-40-9 540849-42-1 540849-43-2
540849-44-3 540849-45-4 540849-46-5 540849-47-6 540748-37-6
540748-38-7 540748-39-8 540748-40-1 540748-41-2 540849-49-8

540748-42-3 540849-51-2 540849-53-4 540849-55-6 540849-57-8
540849-59-0 540849-60-3 540849-62-5 540849-64-7 540849-66-9
540849-68-1 540849-70-5 540849-72-7 540849-74-9 540849-76-1
540849-77-2 540748-43-4 540748-44-5 540748-45-6 540748-46-7
540748-47-8 540748-48-9 148916-02-3 540748-49-0 540748-50-3
540748-51-4 540748-52-5 540748-53-6 540748-54-7 540748-55-8
540748-56-9 540748-57-0 540748-58-1 amino acid sequence;
polynucleotides and their encoded polypeptides from human tissues
96282-35-8 9002-72-6 homologs; polynucleotides and their encoded
polypeptides from human tissues
540847-62-9 540847-63-0 540847-64-1 540847-65-2 540847-67-4
540847-69-6 540847-71-0 540847-75-4 540847-76-5 540847-77-6
540847-79-8 540847-87-8 540847-88-9 540847-89-0 540847-91-4
540847-95-8 540847-96-9 540847-97-0 540847-99-2 540848-02-0
540848-04-2 540848-06-4 540848-08-6 540848-10-0 540848-12-2
540848-15-5 540848-16-6 540848-18-8 540848-21-3 540848-23-5
540848-25-7 540848-26-8 540848-27-9 540848-29-1 540848-32-6
540848-33-7 540848-35-9 540848-39-3 540848-41-7 540848-43-9
540848-44-0 540848-45-1 540848-47-3 540848-50-8 540848-51-9
540848-53-1 540848-57-5 540848-58-6 540848-59-7 540848-65-5
540848-66-6 540848-68-8 540848-80-4 540848-81-5 540848-83-7
540848-88-2 540848-89-3 540848-98-4 540848-99-5 540849-01-2
540849-10-3 540849-12-5 540849-15-8 540849-17-0 540849-20-5
540849-22-7 540849-27-2 540849-28-3 540849-30-7 540849-32-9
540849-33-0 540849-35-2 540849-39-6 540849-41-0 540849-48-7
540849-50-1 540849-52-3 540849-54-5 540849-56-7 540849-58-9
540849-61-4 540849-63-6 540849-65-8 540849-67-0 540849-69-2
540849-71-6 540849-73-8 540849-75-0 nucleotide sequence;
polynucleotides and their encoded polypeptides from human tissues
540889-79-0 540889-80-3 540889-81-4 540889-82-5 540889-83-6
540889-84-7 540889-85-8 540889-86-9 540889-87-0 540889-88-1
540889-89-2 unclaimed protein sequence; polynucleotides and their
encoded polypeptides from human tissues

16/7/26 (Item 17 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

138201087 CA: 138(14)201087a JOURNAL
Adiponectin ELISA
AUTHOR(S): Omoto, Yasukazu; Uehara, Shigeru; Sumida, Takumi
LOCATION: Biological Research Institute, Otsuka Pharmaceutical Co.,
Ltd.,
Japan,
JOURNAL: BIO Clin. (BIO Clinica) DATE: 2002 VOLUME: 17 NUMBER: 2
PAGES: 156-159 CODEN: BCILCY ISSN: 0919-8237 LANGUAGE: Japanese
PUBLISHER: Hokuryukan
SECTION:
CA209000 Biochemical Methods
CA215XXX Immunochemistry
IDENTIFIERS: review adiponectin ELISA disease diagnosis

DESCRIPTORS:
Diagnosis...
adiponectin ELISA and disease diagnosis
Cytokines...
adiponectin; adiponectin ELISA and disease diagnosis
Immunoassay...
enzyme-linked immunosorbent assay; adiponectin ELISA and disease diagnosis

16/7/27 (Item 18 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

138183509 CA: 138(13)183509h PATENT
Method for diagnosing or monitoring carbohydrate metabolism abnormality
INVENTOR(AUTHOR): Tomita, Motowo; Nakano, Yasuko; Hirose, Hiroshi; Matsubara, Koichi
LOCATION: Japan,
ASSIGNEE: Rebio Gen, Inc.; Keio University
PATENT: PCT International ; WO 200316906 A1 DATE: 20030227
APPLICATION: WO 2002JP8331 (20020816) *JP 2001248047 (20010817)
PAGES: 37 pp. CODEN: PIXXD2 LANGUAGE: Japanese
PATENT CLASSIFICATIONS:
CLASS: G01N-033/53A; G01N-033/577B; C07K-016/18B; C12P-021/08B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS
; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE;
ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI;
CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA209010 Biochemical Methods
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: carbohydrate metab abnormality diabetes diagnosis
adiponectin immunoassay
DESCRIPTORS:
Cytokines...
adiponectin, human; natural type; method for diagnosing or monitoring

```
    carbohydrate metab. abnormality
Immunoassay...
    enzyme-linked immunosorbent assay; method for diagnosing or
monitoring
    carbohydrate metab. abnormality
Hybridoma...
    FERM BP-7660; method for diagnosing or monitoring carbohydrate
metab.
    abnormality
Hybridoma...
    FERM BP-7661; method for diagnosing or monitoring carbohydrate
metab.
    abnormality
Carbohydrates,biological studies...
    metab., abnormality; method for diagnosing or monitoring
carbohydrate
    metab. abnormality
Diagnosis... Test kits... Human...
    method for diagnosing or monitoring carbohydrate metab.
abnormality
Antibodies...
    monoclonal; method for diagnosing or monitoring carbohydrate
metab.
    abnormality
Diabetes mellitus...
    non-insulin-dependent; method for diagnosing or monitoring
carbohydrate
    metab. abnormality
  CAS REGISTRY NUMBERS:
9004-10-8  biological studies, resistance; method for diagnosing or
    monitoring carbohydrate metab. abnormality
504-78-9D  deriv., method for diagnosing or monitoring carbohydrate
metab.
    abnormality
111025-46-8  method for diagnosing or monitoring carbohydrate metab.
    abnormality
? ds

Set     Items   Description
S1        475   SERUM (3N) SAMPLE (3N) (TREATMENT OR PRETEATMENT)
S2        146   RD S1  (unique items)
S3        117   S2 NOT PY>2006
S4        117   RD S3  (unique items)
S5    3720408   4 AND ACID
S6         24   S4 AND ACID
S7          3   S6 AND (IMMUNOASSAY OR ANTIBODY)
S8      55814   ADIPONECTIN
S9       3402   S8 AND (ASSAY OR IMMUNOASSY)
S10      1185   S9 NOT PY>2006
S11       352   RD S10  (unique items)
S12         0   ADIPONECTIN 5N IMMUNOASSAY
S13         0   ADIPONECTIN 10N IMMUNOASSAY
```

```
S14       510   ADIPONECTIN AND IMMUNOASSAY
S15        27   S11 AND S14
S16        27   RD S15  (unique items)
?

---Logging off of Dialog---


? logoff
       18nov09 17:11:13 User226352 Session D1191.3
           $11.36    1.835 DialUnits File5
              $56.12  23 Type(s) in Format  7
           $56.12  23 Types
    $67.48  Estimated cost File5
            $0.84    0.112 DialUnits File6
     $0.84  Estimated cost File6
            $3.20    0.496 DialUnits File24
     $3.20  Estimated cost File24
           $51.08    1.794 DialUnits File34
              $16.56  2 Type(s) in Format  7
           $16.56  2 Types
    $67.64  Estimated cost File34
            $0.60    0.080 DialUnits File40
     $0.60  Estimated cost File40
            $0.71    0.109 DialUnits File41
     $0.71  Estimated cost File41
            $2.43    0.469 DialUnits File45
     $2.43  Estimated cost File45
            $3.04    0.639 DialUnits File50
     $3.04  Estimated cost File50
            $1.37    0.321 DialUnits File65
     $1.37  Estimated cost File65
            $7.69    0.707 DialUnits File71
               $2.60  1 Type(s) in Format  7
            $2.60  1 Types
    $10.29  Estimated cost File71
           $22.32    1.611 DialUnits File72
              $7.66  2 Type(s) in Format  7
            $7.66  2 Types
    $29.98  Estimated cost File72
           $22.62    1.633 DialUnits File73
    $22.62  Estimated cost File73
            $1.93    0.299 DialUnits File76
     $1.93  Estimated cost File76
            $0.69    0.156 DialUnits File98
     $0.69  Estimated cost File98
            $1.99    0.306 DialUnits File103
     $1.99  Estimated cost File103
            $0.58    0.090 DialUnits File136
     $0.58  Estimated cost File136
            $0.34    0.109 DialUnits File143
     $0.34  Estimated cost File143
```

```
          $5.81    1.137 DialUnits File144
     $5.81  Estimated cost File144
          $4.73    1.344 DialUnits File154
             $0.48  2 Type(s) in Format  7
          $0.48  2 Types
     $5.21  Estimated cost File154
          $5.01    1.424 DialUnits File155
     $5.01  Estimated cost File155
          $2.45    0.399 DialUnits File156
     $2.45  Estimated cost File156
          $1.59    0.340 DialUnits File162
     $1.59  Estimated cost File162
          $2.15    0.156 DialUnits File172
     $2.15  Estimated cost File172
          $2.92    0.202 DialUnits File305
             $5.82  1 Type(s) in Format  7
          $5.82  1 Types
     $8.74  Estimated cost File305
          $0.19    0.051 DialUnits File369
     $0.19  Estimated cost File369
          $0.13    0.036 DialUnits File370
     $0.13  Estimated cost File370
          $0.56    0.194 DialUnits File393
     $0.56  Estimated cost File393
         $24.84    1.901 DialUnits File399
            $56.62  19 Type(s) in Format  7
         $56.62  19 Types
    $81.46  Estimated cost File399
          $3.11    0.109 DialUnits File434
     $3.11  Estimated cost File434
          OneSearch, 29 files, 18.060 DialUnits FileOS
     $4.80  TELNET
   $336.94  Estimated cost this search
   $336.94  Estimated total session cost  18.444 DialUnits
Logoff: level 05.27.00 D  17:11:13
```